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The DNA-editing enzyme, Activation-Induced cytidine Deaminase (AID) is essential for 
antibody diversification and plays an important role in immunity. AID is specifically expressed 
in activated B-cells and mutates targeted DNA sites, diversifying the antibody repertoire. Due 
to its mutagenic nature, AID expression is tightly regulated, however, its overexpression has 
been associated with translocation of the c-MYC oncogene, a characteristic of the B-cell 
derived cancer, Burkitt’s lymphoma (BL). Although currently uncharacterised, AID 
overexpression has also been implicated in non-lymphoid cancers including prostate, liver and 
colon. The function of AID in the oncogenic process is not well defined and therefore this 
project is aimed at using cell culture models to study the function of AID in cancer.   
 
AID mRNA and protein expression levels were determined in five cell lines of B-cell origin, and 
16 epithelial cell lines (colon, prostate, head and neck and oesophageal). While AID expression 
was easily detected in the B-cell derived cell lines, no significant expression of both AID mRNA 
and protein expression was found in all the epithelial derived cell lines. The B lymphoblastoid 
cell line, L1439A, which is derived from a healthy donor, and harboured relatively low AID 
expression, was originally selected for ectopic expression of AID. Transfection of this cell line 
using conventional methods and lipid and polymer based transfection reagents was not 
successful, and therefore, nucleofection was used, which caused successful uptake of the AID-
expressing plasmids as well as corresponding controls. However, this method was too harsh 
for the L1439A cell line as it did not survive post-nucleofection. Based on this result, the BL 
cell line Ramos, which expresses relatively low AID compared to the other BL cell lines used 
in the screen, was selected as an alternative. Plasmids constitutively expressing AID, as well 
as their corresponding empty vector, were successfully introduced into these cells using an 
established nucleofection protocol. While cells containing the empty vectors could be 
selected and expanded in culture, cells overexpressing AID underwent apoptosis 
approximately three days post-transfection. This is likely due to the highly mutagenic nature 
of the enzyme. As an alternative approach to studying the function of AID in cancer, a 
knockdown approach was taken, using siRNA. Four potential siRNAs targeting AID were tested 
and one was selected for transient AID knockdown in the Ramos cell line. Ramos cells with 
reduced AID expression were analysed alongside control cells for several features 
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characteristic of cancer cells. Reduction in AID expression caused a decrease in cell 
proliferation, as demonstrated by the WST-1 proliferation assays, and confirmed by the 
incorporation of BrdU and cell cycle profile analysis. The difference in CD10, CD19 and CD20 
were unchanged in the knockdown cells. Furthermore, the knockdown of AID sensitized the 
cells to the chemotherapeutic drug doxorubicin. Interestingly, the expression of 
phosphorylated γ-H2AX, a biomarker of DNA double strand breaks, was significantly reduced 
when AID was knocked down, indicating that reducing AID expression leads to a more stable 
genome. Using the Transwell migration assay, we further demonstrated that cells with 
reduced AID expression had decreased mobility, indicating that possible downstream effects 
of AID overexpression enhances cell migration, a key feature of advanced stages of cancer.  
 
This study therefore provided new insight into the cellular effects brought about by AID in 
cancer and the cellular mechanism by which it may contribute to these. Future studies will 
focus on validating some of the results observed, as well as elucidating the signalling 





Chapter 1: Introduction 
Cancer is the leading cause of mortality worldwide with an estimated 20 million new cancer 
cases by 2025 (WHO) and according to the GLOBOCAN 2012 statistics, there were 8.2 million 
cancer deaths and 14.1 million new cancer cases worldwide during 2012 (Ferlay et al., 2015). 
The GLOBOCAN 2012 statistics were produced by the International Agency for Research and 
Cancer (IRAC) comprised from population-based cancer registries. Cancer, which is defined 
by a rapid progression of uncontrolled cell growth due to genetic alterations, is increasing in 
incidence in the developing world. In these regions, cancer makes up 56 % of all worldwide 
cases and is the second leading cause of death (64% of all cancer deaths worldwide) (Chow, 
2010; Jemal et al., 2011). This rise in the global burden of cancer, especially in the developing 
world is due to the increase in cancer causing lifestyles such as smoking, lack of physical 
activity and the adoption of “westernized” diets (Jemal et al., 2011). Cancer is a disease of 
abnormal gene expression and function, brought about by genetic alterations within the 
genome. Despite widespread research in the causes and consequences of these genetic 
alterations, as well as in the development of new therapies, many cancers remain resistant 
to treatment. Therefore there is a continued need for further research in the field, especially 
in the identification of potential cancer causing genes which may be targeted by therapy.  
 
1.1 AICDA 
Sixteen years ago a protein was identified by Muramatsu et al. (1999) that has since been 
described as one of the possible “driver” genes for certain types of cancers. This protein is 
called Activation-Induced cytidine Deaminase (AID) which is located on the AICDA locus on 
chromosome 12 and is made up of five exons (Figure 1.1). The transcription of the gene has 
been found to be regulated by four distinct regulatory regions identified within the locus 
(Maul and Gearhart, 2010). The translated 24 kDa protein is a DNA/RNA-editing enzyme which 
belongs to the apolipoprotein B mRNA-editing catalytic subunit (APOBEC) family (Fritz and 
Papavasiliou, 2010; Endo et al., 2011). Of the 11 human cytidine deaminases within this 
family, AID is the only one with DNA-modifying activities under physiological conditions and 
is fundamental in the process of antibody specificity and diversification (Matsumoto et al., 
2010; Endo et al., 2011; Gu et al., 2012). Importantly, AID has been found highly 
overexpressed in Burkitt’s lymphoma (BL), diffuse large B-cell lymphomas (DLBCL), and 
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follicular lymphoma. Its expression has also been implicated in other human B-cell 
lymphomas, such as chronic lympholytic leukemia, Hodgkin’s lymphoma, mantle cell 
lymphoma, mucosa-associated lymphoid tissue lymphoma, mediastinal B-cell lymphoma, 
hairy cell leukemia and acute lymphocytic leukemia (Kotani et al., 2007). In humans, complete 
loss of AID causes type 2 hyper-IgM syndrome (HIGM2), characterized by lack of somatic 
hypermutation (SHM), class switch recombination (CSR) and lymph node hyperplasia (Revy et 
al., 2000). The current literature on AID’s involvement in cancer will be discussed later in more 




Figure 3.1: Schematic diagram of the AICDA gene. Numbers 1 - 5 indicate the position and size of the 
five exons, while the black boxes denote the coding sequence of the AID protein (taken from Faili et 
al., 2002).  
 
1.2 Antibody diversification by affinity maturation 
Antibody diversification is an important process in generating an effective immune response 
against a broad range of pathogens. Transient structures called germinal centres (GC) form 
when introduced to a T cell-dependent antigen. Within these GC cells, antibodies with high 
affinity are produced and differentiate into memory B cells and plasma cells (De Silva et al., 
2015). GC B cells proliferate at a rapid rate, much higher than normal mammalian tissues to 
produce the vast repertoire of antibodies required to mount an effective immune response 
(De Silva et al., 2015). Due to the processes explained below, the body can produce 109 
antibodies, more than the number of genes that make up the entire human genome (Teng et 
al., 2008). Initially, in the bone marrow, the variable (V) diversity (D) and joining (J) gene 
segments of the immunoglobulin H (IgH) locus rearrange and link to the constant (C) region 
of the Cµ chain in a process termed V(D)J recombination (Durandy, 2003). This antigen- and 
T-cell-independent process produces the primary repertoire of antibodies in the form of naïve 
B-cells (Durandy, 2003). Once a naïve B-cell has moved to the periphery and encounters a 
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pathogen, it undergoes a process called affinity maturation (AM), whereby it activates, 
proliferates and forms a germinal center (GC) in the secondary lymphoid organs (lymph 
nodes, tonsils, and spleen) (Durandy, 2003; Maul and Gearhart, 2010). AID is expressed in 
these activated B-cells and is essential for SHM and CSR to occur (Okazaki et al., 2007; Endo 
et al., 2011; Gu et al., 2012; Mechtcheriakova et al., 2012). 
1.2.1 Somatic Hypermutation 
Somatic hypermutation is defined by the generation of multiple point mutations in the 
variable region of the immunoglobulin (Ig) exons (Muramatsu et al., 1999). This occurs when 
RNA Polymerase II unwinds the double stranded DNA (dsDNA) allowing AID access to 
deaminate the cytidine to uracil. As a protective mechanism, AID can only access the cytidines 
at this point in AM as it can only function on single stranded DNA (ssDNA). The resulting 
deamination is then processed through one of three pathways (Figure 1.2). Either DNA 
replication can move over the U-G mismatch and the C:G bases are replaced with T:A bases, 
or alternatively base excision repair can take place with the help of uracil DNA glycosylase 
(UNG) which initiates the removal of the uracil base and production of an abasic site. This 
process may produce a nick in the DNA by the action of apyrimidinic endonuclease 1 (APE). 
The abasic site is then filled by the error prone translesion synthesis polymerase (TLS) which 
may cause multiple single point mutations. The final alternative process involves the 
mismatch repair proteins; these proteins remove the U-G mismatch with the use of 
exonuclease 1 which is then filled by the TLS therefore giving rise to mutations. Double strand 
Breaks (DSBs) are created when nicks occur in close proximity to each other, the mechanism 




Figure 1.4: Diagram representing the three possible pathways in SHM. They are either a C:G to T:A 
transition, multiple point mutations by the mismatch repair proteins, or base excision repair, with the 
help of UNG and APE which creates an abasic site (taken from Gu et al., 2012).  
1.2.2 Class-switch recombination 
CSR is the second AID mediated process that occurs in AM, whereby the exons of the heavy 
chain constant region (CH) are replaced by alternative C regions of another Ig isotype 
(Muramatsu et al., 1999; Durandy, 2003). C region replacement is possible by recombination 
of two different switch regions (S regions) and the removal and deletion of the intervening 
DNA sequence (Figure 1.3). This allows the replacement of the Cµ with either of Cγ, Cα, or Cε 
which converts the IgM isotype into IgG, IgA or IgE respectively, and this replacement will not 
alter the antigen specificity (Durnady, 2003).  
 
In 2004, Ramiro et al., showed that AID is essential for antibody diversification, by working 
with BALB/c mice, which are especially susceptible to IL-6 stimulation. BALB/c AID+/+ 
transgenic mice stimulated with IL-6 induced c-myc/IgH translocations. BALB/c AID-/- mice 
stimulated with IL-6 developed normal B-cells, however, they failed to produce SHM or CSR, 
the processes which have been shown to be important in antibody diversification (Ramiro et 





Figure 1.5: Diagram showing CSR. AID causes double strand breaks in the switch regions of the IgH 
gene and the intersecting piece of DNA is removed. The V(D)J region is joined to a new CH region 
forming a different IgH isotype (taken from Stevnezer, 2011).  
 
Over and above AID’s role in antibody diversification, it has been shown to mutate non-
immunoglobulin loci in B-cells (Fritz et al., 2013) and there is mounting evidence suggesting 
AID is expressed in other normal tissue types (Robbiani and Nussenzweig, 2013). In murine B-
cells, AID was shown to act in a broad way on the entire genome, relying on two mechanisms 
of protection, selective targeting of AID, and high-fidelity repair (Liu et al., 2008). Even with 
these protective mechanisms, 25 % of all the genes expressed in the activated B-cells were 
found to still be mutated by AID activity (Liu et al., 2008). Murine ovaries have 50 - 70 % higher 
AID expression in comparison to spleen cells (Orthwein and Di Noia, 2012). This indicates that 
AID has a potentially important physiological role in these cells, however, it is as yet unknown 
what this role could be. Under oestrogen stimulation, AID levels are increased in breast tissue 
which increases even further in the ovaries (Orthwein and Di Noia, 2012). Various other 
organs, including prostate, heart and lungs express AID, however the associated physiological 




Additionally AID has also been implicated in DNA methylation: it has been proposed that AID 
can convert 5-methylcytosine (5-mC) in ssDNA to thymine thus allowing one of the T-G 
mismatch-specific glycoslyases to form an abasic site with the removal of 5-mC (Fritz and 
Papavasiliou, 2010; Ramiro and Barreto, 2015). This abasic site is then filled with an 
unmethylated cytidine, thus demethylating the cytidine through a deamination event (Fritz 
and Papavasiliou, 2010). Although a role during development has been proposed, AID 
deficient mice develop normally and therefore AID cannot be the only enzyme responsible 
for epigenetic reprogramming via demethylation during development (Fritz et al., 2013). 
Interestingly, Fritz et al. (2013) has shown that AID does not regulate DNA methylation in 
activated B-cells even though there is a high concentration of AID in these cells (Fritz et al., 
2013). A study independent of the Fritz group, produced at the same time, which was 
performed by Hogenbirk et al. (2013), came to the same conclusions as the Fritz et al. (2013) 
research team. Thus although AID has been shown to demethylate non-lymphoid cells, a 
possible reason for the lack of this mechanism observed in lymphoid cells may be that there 
is a co-factor required for AID-dependent demethylation (Ramiro and Baretto, 2015). AID has 
also been shown to play a role in early development having been conserved in lower 
vertebrates, this indicates more functions for AID outside of just the immune system (Fritz 
and Papavasiliou, 2010). Research into the exact link between AID and demethylation is 
ongoing. 
  
1.3 The many levels of AID regulation 
AID has a powerful mutagenic effect on DNA. This effect promotes tumourigenesis, thus AID 
requires fine regulation to prevent aberrant expression. Extensive studies have been carried 




Several elements that regulate AICDA transcription have been identified. Comparison of the 
50 kb up- and downstream of the human AICDA gene to the mouse homolog, identified four 




Figure 1.6: Diagram showing the mouse and human AICDA loci. Blue boxes are the exons, green boxes 
are the putative CpG islands, black and grey arrows indicate the transcription start sites for each 
ortholog, and the four conserved regions are in red (taken from Yadav et al., 2006). 
 
Region one (R1) is found immediately upstream of the coding region (Figure 1.4) and 
luciferase reporter assays indicate that this region is most likely involved in basal transcription 
(Tran et al., 2010).  Region two (R2) is located within the first intron of AICDA and contains 
both positive and negative regulatory elements and seems to be involved in expression of AID 
in activated B-cells (Tran et al., 2010). In disputing studies, Crouch et al. (2007) showed that 
region three (R3), located downstream of the coding region, is essential for AID expression, 
however, Tran et al. (2010) reported no enhancer activity in this region in their luciferase 
assays (Tran et al., 2010). Region four (R4) which is located approximately 8 kb from the 
transcription start site has been described as a transcriptional enhancer (Tran et al., 2010).  
Regulation via miRNA 
MiRNA molecules have also been identified as regulators of AID expression (Teng et al., 2008). 
MiRNAs are 20 - 23 nucleotides in length and originate from the non-coding sequences in 
introns and non-translated regions of mRNA transcripts. These miRNA molecules generally 
bind to 3’-untranslated complementary sequences resulting in either mRNA degradation or 
inhibition of translation (Bartel, 2004; Stavnezer, 2011). There are four miRNAs that have 
been identified as AID regulators, miR-155, miR-361, miR-181b and miR-93 (Stavnezer, 2011). 
MiR-155 has been shown to be expressed concurrently with AID and destabilizes the protein 
at the 3’ UTR (Dorsett et al., 2008) with mutational studies of miR-155 causing deregulation 
of AID expression and disruption of CSR and AM (Teng et al., 2008). In addition, miR-361 has 
been shown to destabilize AID in much the same way as miR-155 (Basso et al., 2012). MiR-93 
functions in a similar manner to both miR-155 and miR-361, whereby it interacts with the 3’ 
untranslated region (UTR) of AID to block expression (Borchert et al., 2011). Interestingly miR-
181b expression has been shown to decrease during B-cell activation as opposed to the other 
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miRNAs described, however, it functions in the same way by downregulating AID thus 
allowing AID to aid in CSR and SHM (Dorsett et al., 2008).  
   
Post-translational regulation 
AID is also regulated post-translationally, by both cellular compartmentalization and 
phosphorylation (Aoufouchi et al., 2008). The AID protein is mostly found in the cytoplasm 
and there are two regions that control localization: a nuclear localization signal in the N-
terminus, and a nuclear export signal in the C-terminus (Maeda et al., 2010). AID is also 
unstable in the nucleus with the half-life of the protein being three times shorter when 
compared to the cytoplasm (Aoufouchi et al., 2008). Another level of post-translational 
modification is dependent on multiple co-factor proteins. For instance, the recruitment of AID 
to DNA, its transport into the nucleus, and identification of its target sites have been found to 
be dependent on several proteins, namely RNA Polymerase II, RPA, CTNNBL-1, protein kinase 
A and GANP (Maeda et al., 2010). Phosphorylation of AID, at residues Ser38 and Tyr184, have 
been found to regulate the protein as the unphosphorylated form is unable to effectively 
deaminate transcribing dsDNA (Stavnezer, 2011). 
 
1.4 The target of AID  
AID specifically targets G-loops formed in DNA. These are characterized by the G-rich non-
template strand of the R-loop structure, specifically in the Sγ3 region of the IgH gene 
(Duquette et al., 2005; Gómez-González and Aguilera, 2007). Targeting occurs when RNA 
Polymerase II binds to the transcribed strand of AICDA, this causes the non-transcribed strand 
to form an 11 nucleotide piece of ssDNA, creating a transcription bubble. The transcribed DNA 
strand is G-rich, which complements the S region of the IgH transcript, thus hybridizing to 
each other forming an R-loop structure. This R-loop structure opens up longer stretches of 
ssDNA which AID can then target. AID can target both the transcribed and non-transcribed 
strand with the latter being targeted 1.4 fold more frequently (Stavnezer, 2011). Other studies 
have shown that AID also targets other regions within DNA, either CpG islands or consensus 
sequence motifs. The majority of CpG islands targeted by AID are either directly at the CpG 
island position, or in close proximity (≤ 4 nucleotides) (Greisman et al., 2012). Consensus 
sequences which direct the action of AID in the same way as CpG islands have been identified 
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(Greisman et al., 2012). It has also been shown that c-MYC contains regions very similar to 
the S regions targeted in AID thus upon B-cell activation, AICDA and c-MYC are both 
transcribed and AID can target the S regions of AID and the G-rich regions of c-MYC. 
Additionally IgH and c-MYC are in close proximity to one another in the nucleus during this 
process, allowing small nicks to form which create DSBs and allow reciprocal translocations 
to occur (Duquette et al., 2005; Wang et al., 2009).   
 
1.5 AID overexpression in Burkitt’s lymphoma 
AID has been implicated in multiple cancers, more notably in BL, a type of non-Hodgkins 
lymphoma (NHL). This disease is defined by translocations between the c-MYC oncogene, and 
the IgH locus in B lymphocytes, and in 80 % of cases, a t(8;14) translocation occurs, with the 
remaining 20 % comprised of t(8;22) or the t(2;8) translocations (Taub et al., 1982; Blum et 
al., 2004; Spender and Inman, 2014). In 2012 alone there was an estimated 386 000 cases of 
NHL, accounting for 2.7 % of all cancers (Ferlay et al., 2015). As opposed to most cancers 
where increased age heightens the risk of development, BL is trimodal, with three distinctly 
different onset ages, infancy, adulthood and old age (Donadoni et al., 2013). Burkitt’s 
lymphoma has been classified into three different subtypes: endemic, sporadic and HIV-
related. The endemic form is the most common childhood cancer in equatorial Africa as well 
as Africa as a whole, and is characterized by rapidly growing neoplasms predominantly 
affecting the jaw and abdomen which without treatment is fatal within months (Blum et al., 
2004; Wright et al., 2009). These cases have been shown to be predominantly in children, 
with a total of 70 % new cases and deaths affecting this age group (Jemal et al., 2012). Almost 
all endemic BL have EBV infections (Molyneux et al., 2012), although EBV is not BL specific 
(Robbiani et al., 2015). Malaria on the other hand has also been strongly associated with 
endemic BL development, however, its role has remained elusive (Robbiani et al., 2015). 
Robbiani et al. (2015) found that infection with Plasmodium does not induce cancer 
development, but require the addition EBV or other mutational events for BL to develop 
(Robbiani et al., 2015). Sporadic BL has been shown to have no specific geographical 
distribution and affects the abdomen predominantly. HIV-related BL, which is more relevant 




1.6 Burkitt’s lymphoma in an HIV context 
BL is classified as an aggressive AIDS-related lymphoma (HIV-BL). With BL accounting for 30 % 
of all lymphoproliferative malignancies diagnosed in HIV-positive patients and with South 
Africa having more people living with HIV than any other country, this cancer is especially 
relevant locally (Dorrington et al., 2001; Lim et al., 2005; Donodoni et al., 2013; Spender and 
Inman, 2014). BL is 1 000 times more common in HIV patients than the general population 
(Beral and Peterman, 1991). In Western countries the manifestation of HIV infection is often 
the first clinical symptoms of BL (Donadoni et al., 2013). 
 
Prior to the introduction of highly active antiretroviral therapy (HAART), the chance of 
developing NHL was 60 - 200 times higher than in HIV-negative patients (Donadoni et al., 
2013). HAART which consists of a combination of several antiretroviral drugs, was prescribed 
worldwide in 1996 and greatly improved the outcome of HIV-positive patients. This treatment 
improved patients’ host immune response, reduced the development of opportunistic 
infections and decreased the incidence of HIV-related NHL (Donadoni et al., 2013). 
Additionally, it allowed HIV-positive patients with cancer to receive chemotherapy which 
improved their prognosis. Over the years the treatments have changed with high income 
countries using more advanced techniques compared to lower income countries (Molyneux 
et al., 2012). Montoto et al. (2010), retrospectively looked at HIV-BL patients undergoing 
intensive CODOX-M/IVAC (cyclophosphamide, doxorubicin, vincristine and methotrexate) 
treatment while on HAART, and the results showed a 52 % survival rate. The 
chemotherapeutic treatment CHOP (cyclophosphamide, doxorubicin, vincristine and 
prednisone), is less intensive and has shown more frequent relapses and lower survival (Dave 
et al., 2006). The use of CHOP correlated to AID expression was determined in patients with 
diffuse large B-cell lymphoma (DLBCL) which is also classified as an aggressive AIDS-related B-
cell lymphoma. With the advent of HAART in HIV-positive patients the survival rate increased 
significantly (Lim et al., 2005; Gopal et al., 2013) and found that elevated AID expression 
resulted in a poorer response to CHOP treatment (Kawamura et al., 2015), highlighting a 
possible reason for such a low response in BL which by definition have high AID expression 
levels. There has also been an improvement in treatment during the contemporary era (2005 
– 2010) with increased infusional and intensive regimens with greater use of rituximab, which 
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was the first monoclonal antibody approved for therapeutic use in cancer patients as this 
targets the CD20 marker on the surface of B-cells (Smith et al., 2003), in combination with 
HAART (Barta et al., 2015, Schommers et al., 2015).  Although there are currently multiple 
treatment options for HIV-BL patients, these treatments are inadequate and further therapies 
need development. A possible mechanism of action in HIV-BL patients is that high HIV viral 
loads cause a chronic antigenic stimulus, thus increasing AID expression, and leading to 
enhanced c-MYC-IgH translocations. Additionally when the CD40 ligand was incorporated into 
an HIV virion, it was shown to be able to activate AID (Epeldegui et al., 2010). In that particular 
study, HIV virions containing the CD40 ligand were combined with circulating B-cells, which 
resulted in increased gene expression of AID as well as increased AID protein. Contrary to 
what is expected, it has been observed that the risk of developing HIV-BL increases with the 
increase in CD4 count (majority ≥ 250 per µl CD4, risk lowers at ≤ 50 per µl CD4, with only 15 
% of patients having a CD4 count of < 100 per µl) which is in contrast to other HIV-NHL, 
indicating that a functional immune system may in fact be either a cause of HIV-BL or 
facilitating the progression of cancer (Donadoni et al., 2013). Despite these reports, there is 
very little evidence, at the pathological and molecular levels, supporting these claims. It is 
therefore essential to focus research on elucidating the molecular mechanisms of HIV-BL 
pathogenesis if better therapy is to be developed.  
1.7 Relationship between AID and c-MYC translocation 
In transgenic AID mice, expression of AID was identified as critical for the translocation 
T(12;15), which corresponds to the human t(8;14) translocation region characteristic of BL 
(Kotani et al., 2007). In 2006, Ramiro et al. retrovirally transduced AID into BALB/c AID-/- mice, 
upon stimulation with LPS and IL-4, a 10-fold overexpression of AID was induced and de novo 
c-myc-IgH reciprocal translocations were produced. This reiterates that AID is required for 
both SHM and CSR and aberrant expression of this protein can potentially cause the reciprocal 
translocations that are found in BL patients (Ramiro et al., 2006).  Interestingly, in a 
retrospective study, Epeldegui et al. (2007), found elevated AID expression in the peripheral 
blood mononuclear cells of HIV-positive patients who were later diagnosed with NHL. The 
levels of AID were elevated as compared to AIDS patients who did not develop NHL and HIV-
negative patients. Additionally, AID expression differed depending on the subtype of NHL, 
with those who developed BL having the highest levels. In an earlier study, Müller et al. (1995) 
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investigated the presence of the t(8;14) translocation in 114 HIV-positive patients compared 
to 99 HIV-negative individuals and found a fivefold greater incidence of the translocation 
among the HIV-positive patients (10.5 % in HIV-positive versus 2 % in HIV-negative). In that 
study, AID expression was not implicated since AID was only subsequently discovered in 1999 
(Müller et al., 1995; Muramatsu et al., 1999). It has been shown that IL-6 levels are increased 
in HIV positive patients, and as previously mentioned, this specific interleukin has been 
implicated in AID upregulation (Breen et al., 1990; Ramiro et al., 2004). These separate studies 
infer that HIV infection lead to an increase in AID expression, thus increasing the chance of 
aberrant CSR and SHM occurring and thus development of NHL. The type of NHL is also 
correlated to the level of AID expression, with higher AID expression seen in patients who 
developed BL (Epeldegui et al., 2007).   
 
1.8 Aberrant expression of AID in other non-lymphoid cancers 
Although the function of AID is well defined in B-cells, its overexpression has been linked with 
cancers of mainly lymphoid origins (Shimizu et al., 2012). But more recent literature has also 
implicated AID overexpression in the development of several cancers of non-lymphoid origin, 
which are associated with an increased immune response and inflammation. For example 
aberrant expression of AID has been identified in cancers affecting the gastric epithelial tract 
due to inflammation caused by the hepatitis C virus (HCV) and Helicobacter pylori  (Marusawa, 
2008; Endo et al., 2011; Kim et al., 2014; Nagata et al., 2014). A key feature of inflammation 
induced cancer is the immune response regulator NF-κB (Shimizu et al., 2012). As NF-κB has 
been shown to regulate AID expression, which itself is expressed under the stimulation of 
inflammation, it is not surprising that it has been detected in epithelial cells with chronic 
inflammation (Chiba and Marusawa, 2009; Shimizu et al., 2012). NF-κB has been shown to be 
activated in epithelial cells under chronic inflammation (Shimizu et al., 2012), thus implicating 
AID as a possible driving force behind oncogenesis. Studies have shown that AID is 
overexpressed in the gastrointestinal tract (GIT) (Fichtner-Feigl et al., 2015), with high AID 
expression in gastric adenocarcinoma (Batsaikhan et al., 2014).  
 
In mice, ectopic expression of aid causes tumours to develop in various organs, including the 
liver (Endo et al., 2007). Additionally, the expression of endogenous AID could be induced in 
15 
 
human hepatocytes upon treatment with tumour necrosis factor-α, via NF-κB activation, and 
this expression was even more enhanced in the presence of HCV (Kou et al., 2007). AID is also 
overexpressed in oral squamous cell carcinoma (Nakanishi et al., 2013). The oral cavity is 
exposed to external elements such as microbes and chemicals which trigger inflammatory 
responses thus inducing AID expression which may contribute to transformation of those cells 
(Nakanishi et al., 2013). Babbage et al. (2006), found that Ig rearrangements normally 
associated with B-cells were identified in breast cancer cell lines overexpressing AID at a 
comparable level to a known AID overexpressing cancerous cell line. Muñoz et al. (2013) 
showed that AID is needed for the epithelial-to-mesenchymal transition in mammary 
epithelial cells which both indicate that AID may play a role in breast cancer development. 
Furthermore, Shinmura et al. (2011), found that AID mRNA transcripts were detected in 29.4 
% of lung cancer cell lines and 31.4 % of primary lung cancer patients indicating a possible 
role in lung cancer. Studies in transgenic mice, where AID was constitutively and ubiquitously 
expressed, found the development of malignancies in the skin, liver, lung and GIT (Morisawa 
et al., 2008). It also appears that AID causes specific nucleotide changes dependent on the 
organs where AID is over expressed which were identified by investigating at the genotypic 
changes in organ specific cancers that developed in these transgenic mice. Double stranded 
DNA breaks have been shown to be associated with certain epithelial cancers, such as in the 
prostate, however, an association between AID and epithelial cancer development has not 
been characterised.  
 
1.9 Conclusion 
AID is essential for antibody diversification, however, if not appropriately regulated and 
overexpressed, AID may erroneously target proto-oncogenes, such as the c-MYC gene, 
leading to cellular transformation and the development of malignancies. Although a link 
between AID and c-MYC translocation has been established, little is known about other 
cellular consequences as a result of AID overexpression. Therefore more detailed studies on 
its expression and function in carcinogenesis is needed. 
 
1.10 Aims and objectives of the proposed research 
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As described earlier, AID is highly overexpressed is BL, which is of high prevalence among HIV-
positive individuals. Although there have been significant advances in the treatment of HIV-
negative patients suffering from BL, the prognosis of HIV-positive patients with BL remains 
poor, and this is despite the introduction of HAART. Therefore there is an urgent need for 
further research in elucidating the molecular mechanism of HIV-BL, and studying the function 
of AID in BL is one way of achieving this, with the ultimate aim to use the findings to design 
more effective therapies.  
 
As a means to understand the mechanisms by which AID may be leading to cellular 
transformation, the proposed project aims to create cellular models which will be used to 
study cellular and phenotypic changes brought about by AID overexpression, in order to study 
the molecular mechanisms and pathways responsible for the observed changes.  
 
The specific objectives are as follows:  
 
1. To screen a panel of Burkitt’s lymphoma cell lines, and a panel of epithelial derived 
cancer cell lines, for AID expression. Based on the result, one cell line from each 
category will be selected for ectopic AID expression.  
2. To establish AID overexpressing cell lines and study cellular characteristics 
associated with cancer, including cell proliferation and viability, migration, genome 
integrity, B-cell phenotype (CD marker expression) and sensitivity to a 
chemotherapeutic drug. 
3. To establish AID knockdown models to study AID functions as outlined in objective 






Chapter 2: Materials and Methods 
2.1 Cell culture 
2.1.1 Cell line culturing and medium 
A total of 23 cell lines were utilised in this study. The normal EBV-immortalised 
lymphoblastoid cell line (L1439A) was created at the University of Cape Town, in the Chemical 
Pathology Department by Ms Ingrid Baumgarten using an adapted protocol (Freshney, 2010). 
The Ramos cell line (ATCC® CRL-1596™) was obtained from the American Type Culture 
Collection (ATCC, US), the remaining three Burkitt’s lymphoma (BL) cell lines (BL2, P3HR1 and 
Seraphina) were kindly donated by Professor Bernheim (French Institute of Health and 
Medical Research), three of the prostate cell lines (PNT1A, PNT2 and PC-3) were kindly 
donated by Associate Professor Sharon Prince (University of Cape Town) and two prostate 
cell lines (LnCaP and Du145) were kindly donated by Dr Luiz Zerbini (University of Cape Town).  
The colon cancer cell lines (Caco-2, DLD-1, Colo205, Colo206F, HT-29 and LoVo), oesophageal 
cancer cell lines (KYSE-30, KYSE-520, OE19 and OE33) and head and neck cancer cell line 
(UMSCC22b) were kindly donated by Professor Stoecklein (Heinrich-Heine University 
Düsseldorf). The culture conditions for each cell line is detailed in Table I below. Two types of 
medium were used, Dulbecco’s Modified Eagle Medium (DMEM) or Roswell Park Memorial 
Institute (RPMI) medium supplemented with between 10 % to 20 % foetal bovine serum (FBS) 
















Table I: Information and growth conditions for cell lines used in this study.  













DSMZ: ACC-625 Suspension RPMI (20 % FBS) 
P3HR1 ECACC: 86010701 Suspension RPMI (10 % FBS) 
Ramos ATCC®: CRL-1596™ Suspension RPMI (10 % FBS) 
Seraphina NCBI: C102 Suspension RPMI (10 % FBS) 
Du145  ATCC®: HTB-81™ Adherent DMEM (10 % FBS) 
LnCaP 
Prostate Cancer Cell 
Line 
ATCC®: CRL-1740™ Adherent RPMI (10 % FBS) 
PC-3  ATCC®: CRL-1435™ Adherent RPMI (10 % FBS) 
PNT1A Normal Prostate Cell 
Line 
ECACC: 95012614 Adherent RPMI (10 % FBS) 
PNT2 ECACC: 95012613 Adherent RPMI (10 % FBS) 
Caco-2 
Colon Cancer Cell 
Line 
ATCC®: CLL-121™ Adherent DMEM (10 % FBS) 
DLD-1 ATCC®: HTB-37™ Adherent RPMI (10 % FBS) 
HT-29 ATCC®: CCL-221™ Adherent RPMI (10 % FBS) 
LoVo ATCC®: HTB-38™ Adherent RPMI (10 % FBS) 
Colo205 ATCC®: CCL-229™ Adherent RPMI (10 % FBS) 
Colo206F ATCC®: CCL-222™ 
Adherent/susp
ension 




ECACC: 93052620 Semi-adherent RPMI (10 % FBS) 
KYSE-520 DSMZ: ACC 371 Adherent RPMI (10 % FBS) 
OE19 ECACC: 94072011 Adherent RPMI (10 % FBS) 
OE33 ECACC: 96071721 Adherent RPMI (10 % FBS) 
UMSCC22b 
Head and Neck 
Cancer Cell Line 
ECACC: 96070808 Adherent RPMI (10 % FBS) 
COS-7 
African Green 
Monkey Kidney Cell 
Line 
ATCC®: CRL-1651™ Adherent DMEM (10 % FBS) 
HT-1080 Fibrosarcoma ATCC®: CCL-121™ Adherent DMEM (10 % FBS) 
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2.1.2 Resuscitation of frozen cell lines 
Each cell line was removed from liquid nitrogen storage, the cells thawed and placed in 4 ml 
of culture medium and centrifuged for between 1 000 to 2 000 rpm for three to five minutes, 
the supernatant was removed and cells were gently resuspended in 1 ml of pre-warmed 
culture medium, then transferred into appropriate culture dishes containing culture medium. 
All cells were incubated at 37 °C in a humidified atmosphere with 5 % CO2. 
 
2.1.3 Sub-culturing 
2.1.3.1 Suspension cell lines 
Confluency of cells in suspension was determined through visualisation under a light 
microscope, cell counting, and as observation of colour change of medium (from red to 
yellow), which contained a phenol red dye as a pH indicator. To maintain healthy cells, a 
proportion of the cells and culture medium was removed once the culture medium turned 
yellow and replaced with fresh culture medium, thus preventing the cells from becoming too 
confluent and entering quiescence.   
 
2.1.3.2 Adherent cell lines  
Once cells reached a confluency of approximately 80 % (80 % of the surface area of the dish 
is covered with cells), the culture medium was removed, the cells were washed using sterile 
1X PBS, trypsinised using 1X Trypsin-EDTA (Appendix A) (cells were incubated at 37 °C with 2 
ml of 1X Trypsin-EDTA for between one to ten minutes, depending on the cell line, and the 
reaction stopped by the addition of culture medium). The cells were then resuspended, and 
an aliquot of the cells transferred into a new culture dish containing fresh medium.  
 
2.1.4 Freezing and storage of the cell lines 
Freezing of cells was performed using between 5 % and 10 % of either DMSO or glycerol as a 
cryopreservative agent, depending on the recommendation of each cell line. Adhesion cells 
were trypsinised as described above, counted, centrifuged and then the appropriate amount 
resuspended in freezing medium. For suspension cells: cells were counted, then centrifuged 
and the appropriate amount resuspended in pre-chilled freezing medium. Cells were counted 
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using the haemocytometer and in general, cells were frozen in 1 ml aliquots at 1 x 106 cells 
per ml in cryovials. The cryovials were cooled to -80 °C overnight using Mr Frosty (Thermo 
Scientific™, US) which uses isopropanol to decrease the temperature of the samples by 1 °C 
per minute. The vials were then stored under liquid nitrogen long term.  
 
2.1.5 Mycoplasma testing 
All cell lines were tested for Mycoplasma contamination. Cells were initially plated in 
Penicillin-Streptomycin (PenStrep) antibiotic free culture medium for a minimum of three 
days in a 35 mm tissue culture dish, thus allowing any mycoplasma present to proliferate to 
an easily detectable level. The principle of mycoplasma contamination determination in 
adhesion and suspension cells are the same, however, the protocols differ as described 
below.  
 
2.1.5.1 Adherent cell lines 
Coverslips were sterilized by soaking in 100 % ethanol and placed in a 35 mm dish and allowed 
to air-dry. Cells were seeded onto the coverslips in PenStrep-free culture medium and allowed 
to grow for a minimum of three days. The medium was removed, cells were fixed in fixing 
solution (Appendix A) for 10 seconds, washed using water, and cells stained using Hoechst 
33342 stain (#H1399, Invitrogen, US) for approximately eight minutes. Cells were then 
washed again in water and mounted on a microscope slide in mounting fluid (Appendix A) 
and visualised.  
 
2.1.5.2 Suspension cell lines 
For suspension cell lines, 1 x 105 cells were grown in PenStrep-free medium for a minimum of 
three days and 3 µl was placed directly onto a clean microscope slide and air-dried, fixed for 
two minutes by adding just enough fixative (Appendix A) to cover the cells, washed with 
water, then stained with Hoechst 33342 stain (#H1399, Invitrogen, US) (Appendix A) for eight 
minutes. The stain was removed with water and the cells air-dried. A clean coverslip with a 





The slides were visualised using a fluorescent microscope (Zeiss Axiovert 200M, Carl Zeiss 
Microimaging, Germany). Hoechst stain binds to all nuclear material and therefore a positive 
mycoplasma result is indicated as fluorescent dots on the cellular membrane and in the 
cytoplasm of the cells. A negative mycoplasma result will only have the nucleus of the cell 
staining positive.  
 
2.2 Total RNA Isolation 
Prior to RNA extraction, all plastic- and glassware used in the RNA isolation were soaked 
overnight in 0.1 % diethylpyrocarbonate (DEPC) solution in water, which inhibits RNases. 
These were then autoclaved to cause hydrolysis of the DEPC due to its toxic nature (Blumberg, 
1987). The High Pure RNA Isolation Kit (Roche, Germany) was used for total RNA isolation of 
all cells, according to the prescribed protocol. For the adhesion cell lines, the cells were 
washed twice with 200 µl 1X PBS and then scraped in 400 µl of Lysis/Binding Buffer. The 
adhesion cells were then placed in the High Pure Filter Tube. A similar procedure was 
performed for the suspension cells; the cells were placed in a 1.5 ml tube and washed with 
200 µl 1X PBS. The majority of the PBS was aspirated and 400 µl of lysis/-binding buffer was 
then added to the cells and vortexed for 15 s. The cells were then placed into the High Pure 
Filter Tube. The procedure was then the same for both the adhesion and suspension cell lines. 
These filter tubes were then placed in the Collection Tube provided in the kit and centrifuged 
for 15 s at 8000 x g. The flow-through was discarded and the RNA in the filter was treated 
with DNase I solution for 15 minutes at approximately 15 to 25 °C. Thereafter, the filter was 
washed with 500 µl of Wash Buffer I, followed by repeating this step twice, first using 500 µl 
of Wash Buffer II and then with 200 µl of the same buffer, this time centrifuging for two 
minutes at 13 000 x g to remove all excess wash buffer. The total RNA was then eluted from 
the filter using 60 to 80 µl of Elution Buffer. The purity and concentration of the samples were 







2.3 Agarose gel electrophoresis of RNA samples 
Agarose gel electrophoresis is a technique whereby nucleic acid is separated according to size 
by using an electric current to pull the negatively charged molecules through the pores of an 
agarose gel. A very small amount of nucleic acid intercalating agent Ethidium Bromide (10 
mg/ml stock; Sigma Aldrich) is added at a dilution of approximately 1:15 000 for visualisation 
under ultra-violet light (UV). A 1 % agarose gel was prepared as described in Appendix A. The 
samples loaded contained 300 ng of RNA made up to a total of 10 µl using 2X RNA loading 
buffer (Appendix A). The samples were then denatured for five minutes at 55 °C before 
loading onto the agarose gel and electrophoresed for approximately one hour in 1X TBE 
running buffer (made up in DEPC treated water) (Appendix A). The gel was visualised over a 
UV-transilluminator.     
 
2.4 Reverse transcription of mRNA samples 
The mRNA found in the total RNA samples isolated from the cell lines were converted to cDNA 
by reverse transcription using the iScript™ cDNA Synthesis Kit (Bio-Rad, US) and oligo (dT) and 
random hexamer primers using a modified MMLV-derived reverse transcriptase. A total of 
200 ng of RNA was used for each sample and Table II below shows the components of one 
reverse transcription reaction. 
 
Table II: Composition of reverse transcription reaction. 
Components Volume per reaction (µl) 
5x iScript  reaction mix 4 µl 
iScript reverse transcriptase 1 µl 
Nuclease-free water 15 µl - x 
RNA template (150 ng) x µl 
Total 20 µl 
 
The recommended reaction protocol was followed, whereby each sample was incubated at 
25 °C for five minutes, followed by 42 °C for 30 minutes and then terminated with a five 
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minute step at 85 °C using the Multigene™ OptiMax Thermal Cycler (Labnet International, 
Inc., US). The resulting cDNA samples were then stored at -20 °C.  
 
2.5 Generation of standard curve for absolute quantification using qPCR 
A standard curve was produced to quantify the total amount of Activation Induced cytidine 
Deaminase (AID) in each sample compared to two housekeeping genes, GAPDH and RPL27.  
 
2.5.1 Conventional PCR 
L1439A cDNA was used as template for amplifying AID, GAPDH and RPL27 using PCR, to use 
in the generation of the standard curves. Standard PCR was performed using the MyTaq™ 
DNA Polymerase (Bioline, UK) and setup as shown in Table III with the primers sets shown in 
Table IV. 
 
Table III: Composition of the MyTaq™ DNA polymerase chain reaction.  
Components Final Concentration Per 25 µl Reaction 
5X MyTaq Reaction Buffer 1 X 5 µl 
Forward Primer (10 µM) 250 nM 1 µl 
Reverse Primer (10 µM) 250 nM 1 µl 
Template DNA  1 µl 
MyTaq Polymerase  1 µl 
PCR-grade Water  16 µl 











Table IV: Primer sequences used in the PCR and qPCR reactions.  














The cycling conditions used are as follows: a pre-incubation step at 95 °C for one minute, 
followed by 30 cycles comprising a denaturation step at 95 °C for 15 seconds, an annealing 
step at 50 °C for 15 seconds and an elongation step at 72 °C for ten seconds.  
 
2.5.2 Purification of PCR products 
PCR products were purified, using the GeneJET™ PCR Purification Kit (Thermo Scientific, US), 
whereby all the remnants of the PCR reactions such as primers and dNTPs are removed. The 
manufacturer’s protocol was followed. Briefly, 38 µl of PCR product was mixed with equal 
volume of Binding Buffer and equal volume of isopropanol, and then transferred into a 
GeneJET purification column, centrifuged for one minute at 14 000 rpm, the flow-through 
discarded and the DNA trapped in the glass fibre was washed with 700 µl of Wash Buffer, 
excess buffer was removed using an additional centrifugation step at 14 000 rpm, and then 
eluted in 40 µl of Elution Buffer. The eluted PCR products were quantified using the 
NanoDrop™ ND-1000 (Thermo Scientific™, US) and stored at -20 °C.   
 
2.5.3 Agarose gel electrophoresis of DNA samples 
Agarose gel electrophoresis is a technique whereby nucleic acid is separated according to size 
by using an electric current to pull the negatively charged molecules through the pores of an 
agarose gel. A very small amount of nucleic acid intercalating agent Ethidium Bromide (10 
mg/ml stock; Sigma Aldrich) is added at a dilution of approximately 1:15 000 for visualisation 
under UV light. A 1 % agarose gel was prepared as described in Appendix A. The samples 
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loaded contained 3 µl 10X DNA loading buffer (Appendix A). The samples were loading onto 
the agarose gel and electrophoresed for approximately one hour in 1X TBE running buffer 
(Appendix A). The gel was visualised over a UV-transilluminator.   
 
2.6 Quantitative real-time PCR (qPCR) 
To quantify the total amount of AID, GAPDH and RPL27 mRNA in each sample the KAPA SYBR® 
FAST qPCR Kit (Kapa Biosystems, SA) optimised for the LightCycler® 480 (Roche, Germany) 
was used. Table V below shows the components of each qPCR reaction.  
 
Table V: Composition of the KAPA SYBR® FAST qPCR reactions.  
Components Final Concentration Per 20 µl Reaction 
KAPA SYBR® FAST qPCR Master Mix 1 X 10 µl 
Forward Primer (20 µM) 200 nM 0.8 µl 
Reverse Primer (20 µM) 200 nM 0.8 µl 
Template DNA  10% of reaction volume 2 µl 
PCR-grade Water  6.4 µl 
Total  20 µl 
 
The qPCR reactions were setup according to Table V in a 96-well plate and sealed using clear 
film. The cycling conditions used were as follows: a pre-incubation step at 95 °C for three 
minutes, followed by 45 cycles made up of a three second denaturation step at 95 °C, and a 
combined annealing and elongation step at 60 °C for 30 seconds where the fluorescent profile 
was acquired at the end point of the elongation step. After the 45 cycles, the samples were 
then subjected to a melting curve. The samples were incubated at 95 °C for five seconds, the 
temperature then lowered to 65 °C for one minute. The temperature was then continuously 
ramped up at a speed of 2.2 °C per second with five fluorescent acquisitions for every °C 
increase until the samples reached the temperature of 97 °C. The qPCR data was captured 





2.7 Protein extraction and quantification 
2.7.1 Protein extraction using RIPA buffer 
Radio-Immunoprecipitation Assay (RIPA) buffer was used for protein extraction due to its 
efficacy as it utilises three non-ionic and ionic detergents which lyse and permeabilise the 
cells. The RIPA solution was prepared according to Appendix A by combining the RIPA buffer 
with a 7X cOmplete™, Mini, EDTA-free, Protease Inhibitor (Roche, Germany) which protects 
the extracted protein samples from degradation by proteases present in the cell lysates. The 
same principles apply to both suspension and adhesion cell lines, however, the processes 
differ slightly as described below.  
 
2.7.1.1 Adherent cells 
Culture plates containing the cells were placed on ice, the medium removed and cells washed 
three times with ice cold 1X PBS. In a 10 cm plate, approximately 500 µl of RIPA solution was 
added and the cells were scraped, transferred into a 1.5 ml tube and stored at -80 °C overnight 
for optimum lysis. Thereafter cells were thawed on ice, centrifuged at 4 °C (12 000 rpm) for 
20 minutes to remove cell debris, and the supernatant aliquoted and stored at -80 °C. 
 
2.7.1.2 Suspension cells 
Cell suspension was transferred into 15 ml Falcon tubes, and centrifuged for four minutes at 
2000 rpm. The supernatant was removed and the pellet was washed three times by 
resuspending in ice cold 1X PBS followed by centrifugation. The cells were resuspended in 
RIPA solution (between 200 µl and 500 µl depending on pellet size), transferred into a 1.5 ml 
tube and stored at -80 °C overnight for optimum lysis. Thereafter cells were thawed on ice, 
centrifuged at 4 °C (12 000 rpm) for 20 minutes to remove cell debris, and the supernatant 
aliquoted and stored at -80 °C.  
 
2.7.2 Protein Quantification 
The bicinchoninic acid (BCA) reagent was used to determine the protein concentrations, using 
the Pierce™ BCA Assay kit (Thermo Scientific™, US). This assay utilises a sensitive and selective 
colourimetric detection where a unique reagent containing BCA detects the reduction of Cu2+ 
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to Cu1+ in an alkaline medium. A standard curve is generated using bovine serum albumin 
(BSA) at a range of concentrations (2000 µg/ml, 1000 µg/ml, 500 µg/ml, 125 µg/ml and 0 
µg/ml). Briefly, Reagent A and Reagent B are combined in a ratio of 50:1 respectively to 
produce the working reagent. In a 96-well plate, 10 µl of protein sample diluted in RIPA buffer 
(1:2 or 1:5) or standard is added in duplicate, followed by 100 µl of working reagent. The plate 
is then incubated at 37 °C for 30 minutes and the colour change is measured using the Glo-
Max®-Multi+ multiplate reader (Promega, US) at a wavelength of 560 nm. The experimental 
sample concentrations are then extrapolated from the standard curve.  
 
2.7.3 Protein extraction using 2X boiling blue buffer 
Protein was extracted directly by placing the cells into loading buffer and boiling at 95 °C, this 
denatures and linearises the proteins which can then be immediately loaded onto a SDS-
PAGE. Although the principle was the same, the method differed for adhesion and suspension 
cells as described below.  
 
2.7.3.1 Adherent cells 
Media was removed and the cells washed twice with cold 1X PBS. In a 10 cm plate, 
approximately 70 µl of boiling 2X blue Buffer (Appendix A) was added, the cells scraped and 
transferred into a 1.5 ml tube. The solution was boiled at 95 °C for ten minutes, pulse spun 
and either used directly on the SDS-PAGE or cooled to room temperature and stored at -20 
°C. 
 
2.7.3.2 Suspension cells 
Cell suspension was transferred into a 1.5 ml tube and centrifuged 1 000 rpm for five minutes. 
The supernatant was removed and the pellet washed twice by resuspending in cold 1X PBS. 
The cells were resuspended in 2X boiling blue buffer (between 30 µl and 60 µl depending on 
pellet size) and boiled for ten minutes at 95 °C, pulse spun and either used directly on the 





2.8 SDS-PAGE and western blotting 
2.8.1 SDS-PAGE 
To visualise proteins, a polyacrylamide gel electrophoresis (PAGE) was performed using an 
anionic detergent, sodium dodecyl sulphate (SDS), to linearise and negatively charge proteins. 
Using the Mini-PROTEAN 3 casting apparatus (Bio-Rad, US), as per the manufacturer’s 
instructions, a 1.5 mm 12 % resolving gel (Appendix A) and a 5 % stacking gel (Appendix A) 
were prepared. Components used in the protein sample preparation were made up according 
to Table VI. Dithiothreitol (DTT) was used as this is a small redox reagent used to reduce the 
disulphide bridges of the proteins.  
 
Table VI: Components of the protein sample preparation for SDS-PAGE.  
Components Volume (µl) 
Protein Sample (20 µg) x µl 
5X SDS Loading Buffer 6 µl 
100 mM DTT 1 µl 
1X RIPA Buffer  1 µl 
Nuclease-free dH2O 35 - x µl 
 
Samples were denatured at 95 °C for ten minutes prior to loading. Five microliters of the 
PageRuler™ Prestained Protein Ladder (Thermo Scientific™, US) and 30 µl of the samples were 
loaded onto the gel with the addition of 5X loading dye to all empty lanes to ensure proteins 
electrophorese vertically. This was then connected to the Bio-Rad power pack and 
electrophoresed for approximately 200 minutes at 100 V. 
 
2.8.2 Protein transfer 
The proteins separated on the gel were then transferred to nitrocellulose (Bio-Rad, US). This 
was achieved by placing the gel and nitrocellulose membrane in the correct order of the 
cassette as shown in Figure 2.1. The cassette is then placed into the Mini-PROTEAN 3 casting 
apparatus (Bio-Rad, US), with cold 1X transfer buffer (Appendix A) and an ice pack. The power 




Figure 2.1: Diagram of a western blot cassette setup. Each item was placed in the order shown to 
ensure the protein was transferred from the gel on the nitrocellulose membrane. This image was 
adapted from the Mini Trans-Blot® Electrophoretic Transfer Cell manual (Bio-Rad, US).  
 
2.8.3 Antibody incubation and visualisation 
Upon completion of the transfer, the nitrocellulose membrane was washed in PBS/Tween and 
then blocked in PBS/Tween containing 5 % fat-free milk powder for one hour (Appendix A) 
with gentle shaking at room temperature. After blocking, the membranes were incubated 
with primary antibody diluted to the desired concentration (Table VII), and incubated 
overnight at 4 °C in blocking solution with gentle shaking. The membrane was then washed 
in PBS/Tween (2 x 10 minutes followed by 2 x 5 minute washes) before incubation with the 
appropriate HRP-conjugated secondary antibody diluted in blocking solution, for one hour at 
room temperature with gentle shaking (Table VII). The membrane was then washed as before 
in PBS/Tween and visualised by enhanced chemiluminescence using the Clarity™ Western ECL 
Substrate (Bio-Rad, USA) as per the manufacturer’s instructions. Membranes were exposed 










Table VII: Primary and secondary antibody concentrations used in this study. 
Protein Primary Antibody Dilution Secondary Antibody Dilution 
AID 1:1000  1:5000 (goat anti-mouse) 
p38 1:5000 1:5000 (goat anti-rabbit) 
γ-H2AX* 1:1000  1:5000 (goat anti-rabbit) 
*For the γ-H2AX protein, TBS (Appendix A) was used in place of PBS for all washes and 
incubations, with antibody diluted in TBS/Tween containing 5 % BSA (Appendix A).  
 
2.8.4 Membrane stripping 
The antibodies were removed from the blot by incubating in 50 °C pre-warmed stripping 
buffer (Appendix A) at 50 °C for 30 minutes, with brief agitation every ten minutes. The 
membrane was then washed twice for ten minutes with PBS/Tween. The blot was able to be 
reused from the blocking stage as described above, in order that the internal loading control 
protein p38 could be detected. The developed film of the western blots were than scanned 
and the intensity of the bands quantified and normalised using the Li-Cor Image Studio Lite 
software (Version 4.0, Germany).  
 
2.9 Plasmid constructs 
pEGFP-N3-AID and pEGFP-N3-Empty were kindly donated by Professor Bernhard Lüscher 
from RWTH Aachen University in Germany. The pcDNA-3.1-AID and pcDNA-3.1-Empty 
plasmids were kindly donated by Professor Reuben Harris from the University of Minnesota 
in the United States. The pCMV-β-gal plasmid was kindly donated by Professor Sharon Prince 
from the University of Cape Town in South Africa.  
 
2.9.1 Restriction enzyme digests of plasmid constructs 
Restriction enzyme digests were performed on the pEGFP-N3-AID and pEGFP-N3-Empty 
plasmids. Two restriction enzymes were selected, EcoRI and NotI, which both used the buffer 





Table VIII: Reaction components for the restriction digest of the pEGFP-N3 plasmids.  
Components Per 30 µl Reaction 
Plasmid Template (500 ng) x µl 
EcoRI (10u/µl) 1 µl 
NotI (10u/µl) 1 µl 
10X Buffer H  3 µl 
Sterile dH2O 25 - x µl 
Total 30 µl 
 
The reactions were incubated at 37 °C for two hours and stopped by the addition of 3 µl 1X 
DNA Loading Dye (Appendix A) and then separated using agarose gel electrophoresis (Section 
2.5.3).   
 
2.10 Sequencing  
The pEGFP-N3-AID plasmid was sent for sequencing using the forward primer for the 
cytomegalovirus (CMV) as this region was upstream of the AID and EGFP tag.  The pEGFP-N3-
AID plasmid was sent to Inqaba Biotec™ (SA) for sequencing. The results were received and 
analysed using Chromos LITE (Version 2.1.1, Technelysium Pty Ltd).  
 
2.11 Transfection 
For successful transfection, cells need to be at optimum confluency (60 – 80 %), upon reaching 
this level, the cells were counted using a haemocytometer and resuspended in culture 
medium lacking FBS or antibiotic. In each well of a six-well plate, 2 ml solution of cells and 
culture medium without FBS or antibiotic were placed and incubated at 37 °C overnight. Each 
transfection reaction contained 3 µl X-tremeGENE HP DNA Transfection Reagent (Roche, 
Germany) added dropwise to 97 µl of culture medium without FBS or antibiotic and incubated 
for five minutes. This solution was then placed into a 1.5 ml tube containing 500 ng of plasmid 
DNA and incubated for a further 15 minutes. After the incubation, 97 µl of the solution was 
added to each well of the six-well plate dropwise and gently mixed. The cell with plasmid DNA 
and transfection reagent were incubated at 37 °C in the CO2 incubator for 30 hours.  
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2.12 WST-1 proliferation assay 
The WST-1 assay was used to measure cell viability as it contains tetrazolium salts which are 
cleaved to formazan dye in the presence of cellular enzymes produced by metabolically active 
cells, thus the more salt cleaved, the greater the colour change which indirectly indicates cell 
viability. 
2.12.1 Standard WST-1 proliferation assay 
The standard protocol for the WST-1 proliferation assay was 100 µl of cells plated at 
approximately 1 x 105 cells per well in a 96-well plate, with the addition of 10 µl of the WST-
1 proliferation reagent (Roche, Germany), incubated for two hours at 37 °C followed by 
measurement of colour change using the GloMax®-Multi microplate reader (Promega, US).  
2.12.2 Antibiotic kill curve using the WST-1 proliferation assay 
 To create a stably transfected cell line, cells in which the AID expressing locus has been 
incorporated into the genome, together with a marker for antibiotic resistance, needed to be 
selected. Both plasmids used in this study contained the G418 antibiotic resistance gene thus 
the sensitivity of untransfected cells needed to be established in order to determine the 
concentration of G418 to use to select stably transfected cells. Cells were plated at 1 x 105 
cells per well in a 96-well plate, and a range of antibiotic concentrations (0-, 50-, 100-, 200-, 
350-, 500-, 750- and 1000 µg/ml) added to each well. For seven days, 100 µl of cells were 
removed daily, transferred to a new well, and 10 µl of the WST-1 proliferation reagent (Roche, 
Germany) was added, incubated for two hours at 37 °C followed by measurement of colour 
change using the GloMax®-Multi microplate reader (Promega, US). 
2.13 Nucleofection 
The nucleofection process utilises electroporation which causes the cell membrane, 
comprised of negatively phospholipids, to re-orientate and become porous which allow the 
entrance of the plasmid (O’Keefe, 2013). Due to the “difficult-to-transfect” nature of B-cells 
(Maurisse et al., 2010), nucleofection using the Nucleofector™ II (Lonza, Germany) system 
was selected. The Amaxa® Cell Line Nucleofector® Kit V (Lonza, Germany) was used for both 
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L1439A and Ramos. L1439A cells were plated at 1 x 106 and Ramos cells were plated at 2 x 106 
cells in a 24-well plate. Five programmes were initially selected for L1439A (V-001, X-001, T-
020, Y-005 and P-016), with X-001 being selected as the final programme. For Ramos, the 
programme O-006 was identified from the literature as the optimal programme (Thapa et al., 
2011). Cells were counted on the haemocytometer, the total cells used for the experiment 
were centrifuged at 1000 rpm for ten minutes and the supernatant aspirated. This 
centrifugation step was repeated for two minutes, with any excess supernatant being 
aspirated. For each sample, 100 µl of Cell Line Nucleofector® Solution V was added and the 
cells were gently mixed. This solution was then added to 2 µg of plasmid in a 1.5 ml tube. The 
solution was then placed into the supplied cuvettes and nucleofected, and then 500 µl of pre-
warmed medium was added to the cuvette. The supplied plastic pipettes were then used to 
remove the cells and place them in a 12-well plate which contained 1 ml of pre-warmed 
medium. The cells were then placed in the CO2 incubator at 37 °C for 48 hours, after which 
the cells were viewed under the fluorescent microscope.  
 
2.14 Cell sorting using flow cytometry 
To isolate successfully transformed cells, with the assistance from Ronnie Dreyer (Flow 
Cytometry Core Facility, Institute of Infectious Disease and Molecular Medicine, University of 
Cape Town) the FACS Aria (BD, UK) flow cytometer was used. This technique uses lasers aimed 
towards cells and detects forward and side scatter of the light, which determines the cell size 
and number. If a fluorochrome such as 7-AAD or GFP are bound to a cell, the channel specific 
for the fluorescence will detect the excited wavelength. The FACS Aria will then use 
electrostatic deflection, dependent on the type of cell required and sort them into different 
containers. The cells from these containers can then be placed back into cell culture and 
expanded.  
 
2.14.1 EGFP tagged cells 
Cells successfully transfected with the pEGFP-N3 plasmid express GFP and can therefore be 
sorted based on fluorescence. These cells were counted, placed in a Falcon flow cytometry 
tube and diluted in 1X PBS. They were then sorted, and then a portion of the latter cells re-
sorted in order to determine the percentage purity.  
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2.14.2 Live and dead cells using 7-AAD 
Cells successfully transfected with the pcDNA-3.1 plasmids (which lacked a fluorescent tag) 
were sorted based on live/dead selection. Thus 15 minutes before sorting, 5 µl of 7-AAD (BD, 
UK) dye was added to the cells in the Falcon flow cytometry tubes. This dye binds to DNA, and 
it is expected that all dead cells have ruptured cell membrane thus allowing the 7-AAD to 
enter and bind DNA. The cells were then sorted where all cells negative for 7-AAD were 
selected. After cell sorting, a subset of the sorted population were re-sorted in order to 
determine the percentage purity. 
 
2.15 Senescence-associated β-galactosidase assay (SA-β-gal) 
To detect senescencent cells, the SA-β-gal assay was performed. The cells were centrifuged 
at 1 000 rpm for five minutes. The medium was aspirated and the pellet resuspended in sterile 
1X PBS twice (Appendix A). After a further centrifugation step, the pellet was resuspended in 
room temperature β-gal fixative (Appendix A) for five minutes. The cells were centrifuged 
again at 1000 rpm for five minutes and washed twice with sterile 1X PBS as described before. 
Room temperature X-gal staining solution (Appendix A) was added and the pelleted cells were 
resuspended and incubated at 37 °C for 24 hours. After the incubation, the cells were counted 
using the haemocytometer. Cells which are senescent express β-galactosidase, which cleaves 
X-gal, thus these will develop a blue stain.    
 
2.16 Annexin V detection assay 
The Annexin V Apoptosis Kit I (BD, UK) was used which contained the Annexin V protein 
conjugated to the Phycoerythrin (PE) fluorochrome. When cells undergo apoptosis, one of 
the earliest features is the translocation of the phospholipid phosphatidylserine (PS) to the 
outside of the plasma membrane, thus becoming accessible for binding by the Annexin V 
protein, which has a high affinity for PS to bind.  
 
Cells were washed twice with cold sterile 1X PBS. An amount of 1 x 106 cells was resuspended 
in 1 ml 1X Binding Buffer supplied in the kit. In a 5 ml Falcon flow cytometry tube, 100 µl of 
cells and Binding Buffer solution were added which equated to 1 x 105 cells. Thereafter 5 µl 
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of PE Annexin V and 5 µl of 7-AAD were added to the cells, the solution was gently mixed and 
incubated at 15 minutes in the dark at room temperature. After the incubation, 400 µl of 1X 
binding buffer was added and the cells were analysed on the FACSCaliber flow cytometry 
instrument (BD, UK). Controls for the experiment were unstained cells to allow for 
compensation and size determination, cells only stained with PE Annexin V (no 7-AAD) and 
cells only stained with 7-AAD (no PE Annexin V).  
 
2.17 Cell profiling 
To detect alterations to the cell cycle profile, cells underwent flow cytometry with the 
assistance from Ronnie Dreyer (Flow Cytometry Core Facility, Institute of Infectious Disease 
and Molecular Medicine, University of Cape Town) using the FACSCaliber (BD, UK). Cells were 
counted and fixed by adding 8 ml of ice cold 80 % ethanol, drop-wise while simultaneously 
vortexing to prevent clumps from forming. The cells were placed at -20 °C overnight. The fixed 
cells were removed and centrifuged at room temperature for five minutes at 1 500 rpm. The 
ethanol was aspirated leaving behind approximately 1 ml of ethanol. The cells were then 
resuspended in the remaining ethanol and transferred to a new 1.5 ml tube. The cells were 
centrifuged at 6000 rpm for one minute and 900 µl of supernatant was aspirated. The cells 
were washed twice with 1 ml of sterile cold 1X PBS and centrifuged at 6 000 rpm for one 
minute. After the last wash, all the supernatant was removed leaving approximately 50 µl of 
1X PBS with the cell pellet. The cells were then resuspended in RNase A (50 µg/ml) diluted in 
1X PBS, dependent on number of cells. The volume of RNase A was twice the first value at 1 
x 104, therefore 200 x 104 cells equalled 400 µl RNase. The cells were incubated for 30 minutes 
at room temperature and the propidium iodide stain (Appendix A) was added, in a volume 
nine times the RNase volume, 20 minutes before analysis on the FACSCaliber (BD, UK). The 
cell solution was then subjected to flow cytometry which dilutes cells in FACS Buffer (BD, UK) 
and passes them singularly through a capillary. Using the forward and side scatter, the 
quantity of the cellular DNA content was acquired using the CellQuest Pro software (Version 






2.18 AID knockdown using siRNA 
To knockdown AID expression, the FlexiTube AID siRNA kit was purchased from Qiagen 
(Germany) which contains four pre-selected non-validated siRNAs. The efficiency of these 
siRNAs in targeting AID needed to be determined. The experiments were initially performed 
using the recommended transfection reagent produced by the same company, HiPerfect 
(Qiagen, Germany), which proved to be sub-optimal, and subsequently the X-tremeGENE HP 
transfection reagent (Roche, Germany), was used. A scrambled siRNA (AllStars Negative 
Control siRNA) (Qiagen, Germany) was purchased to be used as a control.   
 
2.18.1 siRNA knockdown using HiPerfect 
Cells were seeded at 2 x 105 cells per ml in 10 ml of medium. After 18 hours, the cells were 
counted using the haemocytometer and 1 x 105 cells resuspended in 100 µl of medium and 
then plated in a 24-well plate. In a separate 1.5 ml tubes, the siRNA was mixed in 100 µl of 
RPMI (containing 10 % FBS and 1 % PenStrep) after which the HiPerfect transfection reagent 
was added (Table IX), this was performed for each of the four siRNAs. This mixture was 
incubated for ten minutes at room temperature before being added dropwise to each well 
containing the cells, and gently mixed. The cells were then incubated in the CO2 incubator for 
six hours before 400 µl of RPMI medium (containing 10 % FBS and 1 % PenStrep) was added. 
After 42 hours the cells were removed from the CO2 incubator and protein was extracted 
using 2X boiling blue buffer as described in Section 2.7.3. This was subjected to western blot 
analysis to verify knockdown.   
 
Table IX: siRNA concentrations used in the optimisation reaction for each of the four siRNAs.  
Components Tube 1 Tube 2 Tube 3 Tube 4 
siRNA Concentration 375 ng 375 ng 750 ng 750 ng 







2.18.2 siRNA knockdown using X-tremeGENE HP  
Cells were seeded at 2 x 105 cells per ml in 10 ml of medium. After 18 hours, the cells were 
counted using the haemocytometer and 1 x 105 cells resuspended in 450 µl of RPMI 
(containing 10 % FBS and 1 % PenStrep) and were plated in a 24-well plate. In a 1.5 ml tube, 
47.5 µl of RPMI medium and 2.5 µl of X-tremeGENE HP were gently mixed. In a separate 1.5 
ml tube, 50 µl of RPMI was gently mixed with 1000 ng of siRNA. The RPMI and transfection 
reagent mix was added dropwise to the RPMI and siRNA mix and gently mixed, taking care 
not to leave either solution for longer than five minutes before mixing. The solution were 
incubated for 15 minutes at room temperature before adding dropwise to the 24-well plate 
containing the cells. The 24-well plate was then placed in the CO2 incubator for 48 hours. After 
incubation, the cells were removed and protein was extracted using 2X boiling blue buffer as 
described in Section 2.7.3. This was subjected to western blot analysis to verify knockdown.  
 
2.19 IC50 of doxorubicin 
Doxorubicin was diluted from a stock of 58 mg/ml into a working concentration of 250 µg/ml 
in dH2O. Cells were plated at 1 x 105 cells per well in a 24-well plate and a range of doxorubicin 
concentrations (0-, 0.025-, 0.005-, 0.1-, 0.5-, and 1 µg/ml) added to each well. After 48 hours, 
100 µl of cells were removed and transferred to a new well, and 10 µl of the WST-1 
proliferation reagent (Roche, Germany) was added, incubated for two hours at 37 °C followed 
by measurement of colour change using the GloMax®-Multi microplate reader (Promega, US). 
 
2.20 BrdU incorporation assay 
Bromodeoxyuridine (BrdU) is a thymine analog which is incorporated into replicating DNA in 
place of thymidine, and can then be detected using a secondary antibody conjugated to a 
fluorochrome. Coverslips were coated with poly-L-Lysine (Sigma-Aldrich) to enhance the 
ability of suspension cells to adhere to the surface. Sterile coverslips were placed in 100 % 
ethanol, dried and placed in a single layer in a petri dish. The slides were then covered by 
poly-L-lysine (50 µg/ml) and incubated at 37 °C for one hour. The coverslips were removed 
with sterile forceps and air-dried. Once dry, the coverslips could then be used for the 
experiment. The slides were placed in 24-well plates into which cells that had been 
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transfected with siRNA were seeded. The cells were placed in the incubator for 42 hours 
before 10 µM BrdU was added. After eight hours, the supernatant was removed and replaced 
by fixative (Appendix A) and incubated at -20 °C for 20 minutes. The fixative was removed and 
replaced by 2 N hydrochloric acid and incubated for one hour at 37 °C, this was then 
neutralised by 0.1 M borate buffer (Appendix A). The slides were then washed twice using 1X 
PBS containing 0.05 % Tween-20 (PBS/0.05 % Tween) and incubated with 5 % human serum 
for 30 minutes at 37 °C. BrdU incorporation was then detected using an anti-BrdU mouse 
monoclonal antibody (6 µg/ml) (Roche, Germany) diluted in 0.1 % BSA at 37 °C for 30 minutes. 
The cells were then washed twice using PBS/0.05 % Tween, and incubated with a donkey anti-
mouse secondary antibody (AEC-Amersham) conjugated to Cy3 (1:1000 diluted in 0.1 % BSA). 
The cells were then washed twice in PBS/0.05 % Tween and incubated with Hoechst 33342 
stain (#H1399, Invitrogen, US) for ten minutes. The cells were thereafter washed twice with 
PBS/0.05 % Tween and placed onto a slide using Moyial which contained anti-fade. The cells 
were then visualised under a fluorescent microscope (Zeiss Axiovert 200M, Carl Zeiss 
Microimaging, Germany).   
 
2.21 Transwell migration assay 
The Corning® Transwell® assay (Sigma-Aldrich) was performed to determine migratory 
abilities of cells. In a 24-well plate, 600 µl of RPMI (containing 10 % FBS and 1 % PenStrep) 
was placed in each well, and using sterile forceps the Transwell insert was placed into each 
well, ensuring the bottom chamber was submerged taking care that no air bubbles are 
trapped. A total of 15 Transwell inserts were used, with five inserts for the AID-siRNA3 
knockdown cells, five for the scrambled siRNA control cells and five for the untreated Ramos 
cells. A total of 100 µl of cells (approximately 2.2 x 105 cells per ml) were plated into each 
Transwell insert and placed in the CO2 incubator for 48 hours. Two of each condition was used 
as a total control, whereby all the cells were stained to determine total number of cells in 
each well. The Ramos cells then underwent knockdown as described in Section 2.18.2, with 
one difference, the cells were resuspended in 1 % FBS and not 10 % FBS. After incubation, 
each insert was fixed in 100 % methanol for five minutes and then washed in dH2O. The inserts 
were then placed in 0.1 % crystal violet stain (Appendix A) for 30 minutes before washing with 
dH2O. The upper chambers (three inserts from each group) were swabbed using a cotton wool 
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tipped applicator in order to remove the cells on the upper side of the insert. The inserts were 
washed again and swabbed a second time. The inserts were then placed overnight in the fume 
hood to dry and thereafter the crystal violet stain was dissolved in 150 µl of 50 % acetic acid. 
The absorbance of 100 µl of each sample was determined at 600 µm using the Glo-Max®-
Multi+ multiplate reader (Promega, US).  
 
2.22 Determination of CD expression markers 
Cells were subjected to knockdown as described in Section 2.18.2 and placed into the CO2 
incubator. After 48 hours, the cells were removed and placed into 1.5 ml tubes, these cells 
were centrifuged for five minutes at 2 000 rpm, the supernatant was aspirated and washed 
with cold 1X PBS. This centrifugation and washing step was repeated twice, and the cells 
resuspended in 1X PBS. Cells were stained with 5 µl of the conjugated antibodies: CD10-FITC, 
CD19-APC, CD20-PE (Biolegend, US).  The cells were then analysed using the FACSCaliber (BD, 
UK) and data analysed using the CellQuest software (Version 5.2.1, BD, UK).  
 
2.23 Statistical analysis 
2.23.1 SA-β-gal 
The results from the SA-β-gal assay were subjected to a one-way ANOVA and significant 
differences were located using a Tukey post-hoc test (Prism 6, GraphPad, US). 
 
2.23.2 Proliferation 
The results from the proliferation assay with Ramos cells treated with Doxorubicin and 
untreated cells was subjected to a two-way ANOVA and significant differences were located 
using Sidak’s multiple comparison test (Prism 6, GraphPad, USA).  
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Chapter 3: AID Expression in the Epithelial and B Lymphoblastoid Cell Lines 
3.1 Introduction 
The DNA mutagenic enzyme Activation Induced cytidine Deaminase (AID) is expressed 
specifically in activated B-cells and is a key driver in antibody diversification (Shimizu et al., 
2012). Due to the nature of its function, AID is tightly regulated, however, when it becomes 
unregulated, there is an overexpression of AID which has been shown to be associated with 
certain types of cancers (Shimizu et al., 2012). For instance, in Burkitt’s lymphoma (BL), AID 
overexpression has been implicated in the c-Myc/IgH translocation, leading to upregulation 
of the c-Myc oncogene (Robbiani and Nussenzweig, 2013). AID overexpression has also been 
implicated in certain non-lymphoid cancers, often of epithelial origin including prostate, colon 
and liver cancer (Matsumoto et al., 2007; Lin et al., 2009). In these cancers, AID 
overexpression is not associated with the translocation of c-Myc. Therefore the role of AID in 
oncogenesis is still poorly understood.  
 
The aim of this study is to investigate the role of AID in the oncogenic process. The initial idea 
to achieve this aim, was to use AID-overexpressing cell culture models, one of B-cell origin, 
and a second of epithelial origin. To begin to do this, it was important to identify cell lines, 
representative of the cancers in which AID has been implicated, which were suitable for 
ectopic expression of AID. This chapter presents the results obtained when 5 cell lines of B-
cell origin, and 16 cell lines of epithelial origin, were screened for AID expression.  
 
Total mRNA and protein was extracted from all the cell lines and subjected to quantitative 
real-time PCR (qPCR) and western blotting, to determine AID mRNA and protein expression 
levels respectively. The findings are presented in detail below.  
 
3.2 Results 
3.2.1 All cell lines tested negative for mycoplasma infection 
Mycoplasma is a small bacteria (0.15 to 0.30 µm) which localises on the cell membrane 
forming a string circling the cytoplasm (Nikfarjam and Farzaneh, 2012). These bacteria are 
resistant to most antibiotics, thus the penicillin-streptomycin added to the media is not 
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enough to prevent infection. To identify mycoplasma infections, Hoechst stain which binds to 
all nuclear material is added as described in Section 2.1.5. Infections by mycoplasma has been 
shown to change cell physiology and can potentially alter results (Drexler and Uphoff, 2002), 
thus regular mycoplasma tests of all cell lines used in this study (Table I) were conducted. All 
cell lines tested were found to be negative for mycoplasma contamination as only the nucleus 
of each cell could be visualised under fluorescent microscopy using the Hoechst 33342 stain 
(#H1399, Invitrogen, US). Figure 3.1 below is representative of a negative mycoplasma result 
in the EBV-immortalised lymphoblastoid cell line L1439A (A-C) and the Burkitt’s lymphoma 
cell line Ramos (D-F).  
 
 
Figure 3.1: Representative mycoplasma result for L1439A and Ramos. Mycoplasma staining using 
Hoechst Stain in L1439A (A-C) and Ramos (D-F). A & D are fluorescent images, B & E are corresponding 
phase contrast images and C & F are the overlaid images visualised using the confocal microscope. 





3.2.2 Extracted RNA of all but one sample is of good quality and suitable for cDNA 
conversion 
To accurately determine AID mRNA levels in each cell line, total RNA needed to be extracted 
and quantified. The purity and concentration of the total RNA extracted were determined as 
shown in Table X. The 260/280 ratio is a measure of RNA purity, a ratio of approximately 2.0 
is generally accepted as ideal. A value significantly lower would indicate the presence of either 
protein, phenol or another contaminant that absorbs strongly at 280 nm. The 260/230 ratio 
is a secondary measure of purity with the ideal ratio between 2.0 to 2.2. A lower reading 
would be an indication of contaminants that absorb light within the 230 nm spectrum. The 
RNA extracted from all cell lines fell within the acceptable parameters with the exception of 
the BL cell line, P3HR1, which had low 260/280 and 260/230 ratios. RNA extraction was 
repeated in the P3HR1 cell line, however the result remained the same, although the cell line 
seemed to grow well in culture. This low yield of RNA obtained could be that these cells 
appeared much smaller than the other B-cell lines in culture. Despite numerous attempts, 
including the use of a specialised kit for RNA clean-up with a concentration step (RNA Clean 
& Concentrator™-5, Zymo Research, USA) the quality of the RNA could not be improved upon 
















Table X: The purity and concentration of RNA for each of the 21 cell lines used in this study. The 
lowest concentration obtained, which became the limiting factor in cDNA synthesis, was for the 
Burkitt’s lymphoma cell line, P3HR1, as highlighted in red within the table.  









Lymphoblastoid Cell Line 
2.08 2.10 304.60 
BL-2 
Burkitt’s Lymphoma Cell Line 
2.04 2.19 59.50 
P3HR1 1.98 1.89 15.30 
Ramos 2.03 2.27 33.10 
Seraphina 2.09 2.27 1041.30 
Du145  2.10 2.30 1230.20 
LnCaP Prostate Cancer Cell Line 2.13 2.36 234.40 
PC-3  2.08 2.24 1136.70 
PNT1A 
Normal Prostate Cell Line 
2.04 2.22 252.10 
PNT2 2.08 2.28 354.00 
Caco-2 
Colon Cancer Cell Line 
2.07 2.28 536.10 
DLD-1 2.08 2.17 1574.40 
HT-29 2.10 2.24 490.20 
LoVo 2.07 2.24 278.70 
Colo205 2.08 2.24 1161.90 
Colo206F 2.09 2.26 1285.10 
KYSE-30 
Oesophageal Cancer Cell Line 
2.13 2.41 489.60 
KYSE-520 2.13 2.40 155.30 
OE19 2.08 2.18 144.50 
OE33 2.15 2.39 157.60 
UMSCC22b Head and Neck Cancer Cell Line 2.06 2.36 173.70 
 
The quality of RNA was further determined using gel electrophoresis (Figure 3.2 and Appendix 
B, Figures B1, B2, and B3). RNA of good quality and integrity displays two distinct bands 
namely the 28S and 18S ribosomal subunits, with no or minimal smearing. In addition, any 
bands that appear above the 28S rRNA is indicative of genomic DNA contamination. Figure 
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3.2, showing the RNA extracted from the colon cancer cell lines, is a representative result of 
the RNA integrity observed for all the samples and shows characteristics of RNA of good 
integrity that is suitable for use in cDNA conversion and qPCR.  
 
Figure 3.2: Gel electrophoresis of total RNA extracted from the colon cancer cell lines. The two sharp 
bands representing the 28S and 18S ribosomal subunits were observed in a 1 % agarose gel. (Lanes 1 
– 6: Caco-2, DLD-1, HT-29, LoVo, Colo205 and Colo206F).  
 
3.2.3 AID mRNA expression was determined by qPCR 
To determine the absolute amount of AID mRNA being produced within these cell lines, total 
RNA was subjected to qPCR. To accurately quantify and compare AID expression between cell 
lines, two housekeeping genes (GAPDH and RPL27) were selected which have stable 
expression levels (De Jonge et al, 2007). To be able to quantify the copy number for each 
sample, standard curves for all three genes were produced.   
 
3.2.3.1 Generation of standard curves 
Initially total RNA was isolated from L1439A and cDNA reverse transcription performed as 
described in Section 2.4. This cDNA was then used to generate three standard curves, one for 
each of the three genes (AID, GAPDH and RPL27). Initially a standard PCR was performed using 
the qPCR primer sets, amplifying each gene using the cDNA generated from L1439A as a 
template (Section 2.5). The successfully amplified products then underwent a PCR purification 
step (Section 2.5.2). The resulting products (Table XI) were then quantified and the copy 
number calculated according to the following equation: 
 
𝐶𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑛𝑔/µ𝑙 ) × 10−9 (𝑔/𝐿) 
𝐿𝑒𝑛𝑔𝑡ℎ (𝑏𝑝) × 660




Table XI: Copy number calculation for the genes of interest.  
Gene Length (bp) Concentration (ng/µl) 
Copy Number 
(molecules of DNA/µl) 
AID 108 31.6 2.7 x 1011 
GAPDH 133 35.1 2.4 x 1011 
RPL27 123 58.3 4.3 x 1011 
 
Two serial dilutions were produced, a 1:10 serial dilution for AID and a 1:100 serial dilution 
for both GAPDH and RPL27. Figure 3.3 below is a representative qPCR amplification profile 
for the AID serial dilution in duplicate, with Figure 3.4 representing the standard curves 
produced from each gene.   
 
 
Figure 3.3: qPCR amplification profile of AID. Amplification curves of AID utilising a 1:10 serial dilution 







Figure 3.4: Graphically plotted standard curves for AID, GAPDH and RLP27. Standard deviation is 
shown by the error bars and the R2 values for each standard curve is on each graph.   
 
Total RNA from each cell line was then extracted, quantified and quality checked as described 
in Section 2.2 and 2.3. The cDNA generated were then used in the qPCR reaction (Section 2.6) 
with the same volume of product in each reaction allowing us to quantitatively compare 
expression levels between each sample. 
 
3.2.3.2 AID mRNA expression in the B-cell derived cell lines 
A qPCR reaction was setup for the four BL cell lines (BL2, P3HR1, Ramos and Seraphina) and 
the EBV-immortalised human B lymphoblast cell line (L1439A). These samples were run in 
triplicate with all three primer sets (AID, GAPDH and RPL27) as well as each respective 
standard in duplicate. Copy number for each sample was extrapolated from the standard 
curves. AID was then normalised against GAPDH and RPL27 where the percent AID expression 





Figure 3.5: AID mRNA expression in the B-cell derived cell lines. AID mRNA expression was normalised 
to either the housekeeping gene GAPDH (blue bars), or to RPL27 (red bars). Error bars represent the 
standard deviation.  
 
A single amplified qPCR product was confirmed by performing a melt curve (Figure B7) and 
by agarose gel electrophoresis (Figure 3.6). The latter also confirmed that fragments of the 
appropriate sizes were amplified and that no primer dimers were present.   
 
 
Figure 3.6: Verification of qPCR products by agarose gel electrophoresis. Lane 1, 1kb molecular 
weight marker, lanes 2-4; AID qPCR product from the 1 x 106 standard sample, L1439A, and Ramos 
respectively, lanes 5-7; GAPDH qPCR product for the 1 x 106 standard sample, L1439A, and Ramos 
respectively, lanes 8-10; RPL27 qPCR product for the 1 x 106 standard sample, L1439A, and Ramos 
respectively. These samples were electrophoresed on a 1% agarose gel.  
 
3.2.3.3 AID mRNA expression in epithelial derived cancer cell lines  
The literature indicated that AID overexpression is a feature of some types of epithelial 
cancers, especially those associated with inflammation, such as cancers of the gastrointestinal 
tract (GIT), but also prostate cancer (Lin et al., 2009; Shimuzu et al., 2012).The mRNA from 16 
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epithelial cell lines, including colon, oesophageal, prostate and head and neck (Table X) were 
subjected to qPCR to determine the levels of AID which is expressed. Our results in Figure 3.7 
below show that AID mRNA was not present in the majority of these cell lines, except for two 
oesophageal cell lines (OE19 and KYSE-30) which had low levels of AID mRNA.  
 
 
Figure 3.7: AID mRNA expression determined by qPCR for all the epithelial cell lines used in this 
study. AID expression was normalised to each of the housekeeping genes (GAPDH in blue and RPL27 
in red).  
 
The results for Du145 are missing from Figure 3.7 as all three genes failed to amplify in this 
prostate cancer cell line. The qPCR of this sample was repeated with a new aliquot of reverse 
transcribed cDNA, however, the experiment repeatedly failed. The 260/280 and 260/230 
ratios for Du145 were within the acceptable region (2.10 and 2.30, respectively), and the RNA 
gel showed good quality and integrity (Appendix B, Figure B1). When conventional PCR was 
performed, products could be amplified for two of the three sets of primers (Figure 3.8) and 
therefore indicated that only the qPCR reaction was being inhibited. It is of note that the AID 
PCR primer set produced a positive band for AID, thus indicating that AID mRNA may be 
present in this cell line. All the cell lines, including the two oesophageal cell lines which 
showed AID mRNA expression, had total protein extracted to determine whether the 




Figure 3.8: Agarose gel electrophoresis of products from conventional PCR using Du145 mRNA. A 
duplex PCR was performed using primers for GAPDH (133 bp) and AID (108 bp). cDNA derived from 
the Du145 total mRNA extraction was used at varying volumes. Lane 1; 100 bp molecular weight 
marker, lane 2; L1439A, lane 3; Du145 (2 µl), lane 4; Du145 (1 µl), lane 5; Du145 (0.5 µl). These samples 
were electrophoresed on a 1 % agarose gel. 
 
3.2.4 AID protein expression in B-cell derived and epithelial derived cell lines 
In order to determine whether the AID mRNA was being translated into protein, and that the 
mRNA result correlates with the protein result (the functional unit), protein from each cell 
line was extracted, separated by SDS-PAGE and analysed by western blotting. The results are 
presented below.  
 
3.2.4.1 Total protein extraction and quantification 
Total protein was extracted from each cell line using RIPA buffer (Section 2.7.1) and quantified 
using the BCA Assay (Section 2.7.2). Table XII show the protein concentrations obtained, 
which varied between cell lines, with the highest at 9.20 µg/µl for the Colo206F (colon cancer) 




Table XII: Total protein concentration of each cell line used in this study.  







Lymphoblastoid Cell Line 
2.40 
BL-2 




























UMSCC22b Head and Neck Cancer Cell Line 1.86 
 
3.2.4.2 SDS-PAGE and western blotting to determine AID protein expression in the B-cell 
derived cell lines 
Equal concentrations of total protein extracted from the B-cell derived cell lines were 
separated in a 12 % SDS-PAGE (Section 2.8.1) and then transferred onto nitrocellulose 
membranes for western blotting (Section2.8.2). The result is shown below in Figure 3.9 and 
the intensity of the AID bands, relative to the internal control p38 were analysed using the Li-
Cor Image Studio Lite software and displayed as densitographs. AID protein was easily 
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detected from all the samples, but interestingly did not correlate exactly with the qPCR 
results.  
 
Figure 3.9: AID protein expression in L1439A and the Burkitt’s lymphoma cell lines. Western blot 
analysis displaying the AID protein expression levels in the EBV-immortalised B lymphoblastoid cell 
line and the four Burkitt’s lymphoma cell lines. 6 µl of 5X loading dye and 1 µl of DTT was added to 30 
µl of protein (20 µg) in RIPA buffer and boiled at 95 °C for five minutes before being loaded and 
separated on a 12 % SDS-PAGE gel at 100 V for 200 minutes in 1X running buffer. The protein was then 
transferred onto a nitrocellulose membrane (Bio-Rad) for 75 minutes at 100 V in 1X transfer buffer. 
This was then detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad). To detect AID, 
mouse anti-AID (Invitrogen) was used, with a HRP bound goat anti-mouse secondary antibody (Bio-
Rad). The p38 protein was used as a loading control and detected using the rabbit anti-p38 antibody 
(Sigma-Aldrich) and the HRP bound goat anti-rabbit secondary antibody. The signal intensity of the 
bands were analysed using the Li-Cor Image Studio software (Germany), and normalised to p38. This 
densitometric analysis representing AID protein expression is displayed above the western blot.  
 
3.2.4.3 SDS-PAGE and western blotting to investigate AID protein expression in the 
epithelial cell lines 
In the same way as described above for the B-cell derived cell lines, total protein from the 
epithelial cell lines was extracted, separated by SDS-PAGE and processed for western blotting 
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to detect AID protein expression. The result is shown below in Figures 3.10, 3.11 and 3.12, 
and mostly correlates with the result obtained for the mRNA expression using qPCR. A positive 
control sample was included in each western blot. This consisted of either Seraphina or the 
COS-7 cells transfected with the pcDNA-3.1-AID mammalian expression plasmid leading to 
constitutive expression of AID in these cells as described later in Section 4.2.1.  
 
Figure 3.10: AID protein expression in the five prostate cell lines. Western blot analysis displaying 
the AID protein expression levels in the five prostate cell lines (PNT1A and PNT2 are normal prostate 
cell lines, while, LnCaP, Du145 and PC-3 are prostate cancer cell lines) with Seraphina (BL cell line) 
being used as a positive control for AID expression. 6 µl of 5X loading dye and 1 µl of DTT was added 
to 30 µl of protein (20 µg) in RIPA buffer and boiled at 95 °C for five minutes before being loaded and 
separated on a 12 % SDS-PAGE gel at 100 V for 200 minutes in 1X running buffer. The protein was then 
transferred onto a nitrocellulose membrane (Bio-Rad) for 75 minutes at 100 V in 1X transfer buffer. 
This was then detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad). To detect AID, 
mouse anti-AID (Invitrogen) was used, with a HRP bound goat anti-mouse secondary antibody (Bio-
Rad). The p38 protein was used as a loading control and detected using the rabbit anti-p38 antibody 
(Sigma-Aldrich) and the HRP bound goat anti-rabbit secondary antibody.  
 
 
Figure 3.11: AID protein expression in four oesophageal cancer cell lines and one head and neck 
cancer cell line. Western blot analysis displaying the AID protein expression levels in the four 
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oesophageal and the head and neck cancer cell lines with pcDNA-3.1-AID as a positive control for AID 
expression. 6 µl of 5X loading dye and 1 µl of DTT was added to 30 µl of protein (20 µg) in RIPA buffer 
and boiled at 95 °C for five minutes before being loaded and separated on a 12 % SDS-PAGE gel at 100 
V for 200 minutes in 1X running buffer. The protein was then transferred onto a nitrocellulose 
membrane (Bio-Rad) for 75 minutes at 100 V in 1X transfer buffer. This was then detected using the 
Clarity™ Western ECL Blotting Substrate (Bio-Rad). To detect AID, mouse anti-AID (Invitrogen) was 
used, with a HRP bound goat anti-mouse secondary antibody (Bio-Rad). The p38 protein was used as 
a loading control and detected using the rabbit anti-p38 antibody (Sigma-Aldrich) and the HRP bound 
goat anti-rabbit secondary antibody.  
   
Figure 3.12: AID protein expression in the six colon cancer cell lines. Western blot analysis displaying 
the AID protein expression levels in the six colon cancer cell lines with pcDNA-3.1-AID as a positive 
control for AID expression. 6 µl of 5X loading dye and 1 µl of DTT was added to 30 µl of protein (20 µg) 
in RIPA buffer and boiled at 95 °C for five minutes before being loaded and separated on a 12 % SDS-
PAGE gel at 100 V for 200 minutes in 1X running buffer. The protein was then transferred onto a 
nitrocellulose membrane (Bio-Rad) for 75 minutes at 100 V in 1X transfer buffer. This was then 
detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad). To detect AID, mouse anti-AID 
(Invitrogen) was used, with a HRP bound goat anti-mouse secondary antibody (Bio-Rad). The p38 
protein was used as a loading control and detected using the rabbit anti-p38 antibody (Sigma-Aldrich) 
and the HRP bound goat anti-rabbit secondary antibody.  
3.3 Discussion and conclusion 
The expression of the B-cell specific enzyme AID has been associated with the onset of cancer 
due to its mutagenic nature (Shimizu et al., 2012). However, the exact function of AID in the 
oncogenic process has not been well studied. The aim of this part of the study was to identify 
two cell lines, one of B-cell origin, and another of epithelial origin, which can be used to 
ectopically express AID, with the aim to use these models to better define the oncogenic role 




A total of 21 cell lines were used in this study, and all were found to be free of mycoplasma 
infection, which indicates that the qPCR and western blotting results, relating to the 
expression of AID, are likely to be accurate, and not a result of cells growing under conditions 
of stress, as they could if they had been infected with an agent like mycoplasma (Nikfarjam 
and Farzaneh, 2012). 
 
The panel of B lymphoblastoid cell lines were made up of four Burkitt’s lymphoma cell lines 
and one EBV-immortalised B lymphoblastoid cell line derived from a healthy donor. Total 
mRNA was extracted and qPCR analyses performed using primer sets for AID, GAPDH and 
RPL27. All the mRNA extracted was of good quality and integrity, except P3HR1, of which low 
yields and absorbance readings lower than the preferred values were obtained. Re-extraction 
of RNA from the P3HR1 cell line produced no yield changes, which did not improve after being 
subjected to an RNA clean-up kit. As this sample’s integrity was on the border of acceptance, 
it was subjected to RNA integrity gel electrophoresis (Appendix B, Figure B1) which showed 
the sample could be used for further experimentation. A possible reason for this low RNA 
yield could be due to the small size of the cell, and an appropriate number of cells to get a 
higher yield of RNA could not be obtained. The RNA integrity of all the remaining cell lines, 
including P3HR1 were deemed acceptable for qPCR analysis (Figure 3.2 and Appendix B, 
Figures B1, B2 and B3). The qPCR analysis showed that there was AID mRNA expression in all 
five B lymphoblastoid cell lines. To control for sample variation, the same concentration of 
each mRNA sample was subjected to cDNA synthesis and the same volume used in each qPCR 
reaction. This AID mRNA expression was then normalised against the two housekeeping genes 
GAPDH and RPL27 (Figure 3.5). As Vandesompele et al. (2002) stated, there are no ideal 
housekeeping genes as there will always be some variation so for this reason we selected two 
housekeeping genes to control for any experimental variations between samples. Although 
most studies are moving away from using GAPDH as a housekeeping gene, we used both 
GAPDH and RPL27 to normalise AID expression. Ribosomal proteins, such as RPL27 (a gene 
which codes for a component of the ribosomal subunit 60S) are being successfully used as 
housekeeping genes (Rebouças et al., 2013). These two housekeeping genes were selected as 
there was no differentiating between different disease states within a single cell type, but 
rather comparing mRNA expression of AID across different cell types. There were only slight 
and negligible variations between AID expression normalised to GAPDH and RPL27, thus we 
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can accept both these results as accurate. The qPCR result of AID mRNA expression in the four 
Burkitt’s lymphoma cell lines are in agreement with the published literature concerning AID 
overexpression in this cancer (Robianni et al., 2008). Surprisingly, the amount of AID mRNA in 
the EBV-immortalised B lymphoblastoid (L1439A) is comparable to that obtained in the 
Burkitt’s lymphoma cell lines (Figure 3.5). The L1439A cell line is the closest representation of 
a normal B-cell line available for this study. It is interesting that L1439A has such a high AID 
mRNA expression as it would be expected that AID mRNA expression in a normal cell line 
would be less than a cancerous cell line known to overexpress this gene. The reason for this 
high expression could be due to the EBV immortalisation of this cell line. EBV is the only virus 
known to immortalise B lymphocytes, thus one cannot do without this step, as otherwise the 
cells will not be able to propagate in culture (Tosato and Cohen, 2007).  This EBV 
immortalisation step was a caveat, as introducing EBV into these cells may affect other 
downstream processes which could in turn alter AID expression. Studies have shown that two 
small non-polyadenylated RNAs are expressed with EBV infection, namely EBER1 and EBER2 
(Young and Rickinson, 2004). The expression of these EBERs, have been shown to increase 
tumourigenicity, IL-10 expression and improve cell survival (Wu et al., 2007; Brady et al., 
2008). This improvement in cell survival is one of the key features which allowed for the 
transformation of the normal L1439A cells to allow them to propagate in culture. Specifically 
EBER1 has been shown to activate Toll-Like Receptor 3 (TLR3) signalling, which results in an 
induction of type I Interferon (IFN) and proinflammatory cytokines (Iwakiri et al., 2009). Thus 
with AID expression correlated to an increased immune response, the use of EBV in this cell 
line may artificially increase AID expression.  
 
The western blot results confirmed that the AID mRNA in L1439A and BL cells was translated 
into the functional subunit (protein) (Figure 3.9). Though L1439A had high AID mRNA 
expression, it had the lowest AID protein expression when compared to the Burkitt’s 
lymphoma cell lines. Conversely, the Burkitt’s lymphoma cell line BL2 had the highest protein 
expression, but the lowest AID mRNA expression level. It is interesting that AID mRNA 
expression levels and AID protein expression differed within each cell line. AID does undergo 
several post-transcriptional and post-translational regulatory mechanisms which could 
account for this discrepancy. For example four microRNAs (miRNA), miR155, miR361, 
miR181b and miR93, have been described to bind to the 3’-untranslated region of the AID 
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mRNA, causing either mRNA degradation or inhibition of translation (Stavnezer, 2011). The 
AID protein is also subject to post-translational regulation through cellular 
compartmentalisation and phosphorylation (Aoufouchi et al, 2008). The aim with regards to 
the cells of B-cell origin was achieved, in that the L1439A cell line was found to express low 
AID protein levels compared to the BL cell lines, and was therefore a good candidate for the 
ectopic expression of AID. The results of this overexpression are described in the next chapter.  
 
Similarly, the epithelial cell lines representative of various cancers in which AID 
overexpression has been implicated were also analysed for AID expression at both the mRNA 
and protein levels (Figures 3.7, 3.10, 3.11 and 3.12). It would have been ideal to have a 
“normal” cell line for each type of cancer which was screened, as was the case of the samples 
of prostate origin, however, these could not be sourced for this study. Since AID expression was 
undetectable in any of these samples using our methods and in our hands, we suggest that AID does 
not play a significant role in these cancers, contrary to the few reports in the literature (Fichtner-
Feigl et al., 2015). It therefore became unimportant for the normal counterparts of these cell 
lines to be sourced. The mRNA samples for all the epithelial cell lines were found to be of 
good quality after isolation and could be analysed by qPCR, however, Du145 could not be 
amplified in the qPCR reaction. Despite several attempts with various modifications, including 
re-isolation of RNA, qPCR continued to fail for the Du145 sample, while conventional PCR was 
successful when using GAPDH and AID primer sets (Figure 3.8). This result points towards 
some AID expression within this prostate cancer cell line, however, due to the properties of 
conventional PCR, it was not possible to identify the copy number of AID mRNA present in the 
sample. This cell line, with the other epithelial cell lines, were analysed for AID protein 
expression levels. Possible reasons for this failure are the presence of an inhibitor that affects 
only the qPCR reaction but not the conventional PCR. The qPCR and conventional PCR were 
performed using kits from different companies (Kapa Biosystems, SA versus Bioline, UK, 
respectively). The buffer systems in each of the kit would differ, however, the method of 
mRNA extraction was exactly the same for each of the cell lines, thus the only other variable 
is the cell line itself. This cell line possibly produces an inhibitor of the polymerase in the qPCR 
reaction, but the buffer system and enzyme for the conventional PCR polymerase, which are 
usually more robust than qPCR reagents, was not affected in the same way. Moreover, 
conventional PCR is carried out for many cycles, which allows for amplification of even a very 
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small amount of template, while this is not the case in qPCR. Due to time and cost constraints 
no further qPCR tests were performed, however, a possible test for the future would be to 
decrease the volume of sample added to determine whether the inhibitor could be diluted 
out of the reaction. The result of the conventional PCR indicates that this cell line possibly 
express a certain level of AID mRNA, however, no protein could be detected by western 
blotting. 
 
The rest of the epithelial sample qPCR reactions were successfully analysed and all except two 
cell lines, OE19 and KYSE-30, were negative for AID mRNA expression (Figure 3.7). The OE19 
and KYSE-30 cell lines are oesophageal cancer cell lines, and while AID mRNA was detectable, 
the levels were significantly lower than what was observed in the B-cell derived cell lines.  
 
However, no AID protein expression could be detected in any of the epithelial derived cell 
lines. Thus although some papers reported a correlation between AID expression and certain 
types of epithelial cancers (Tomlins et al., 2005; Lin et al., 2009; Fichtner-Feigl et al., 2015), 
our observations point to an unlikely role for AID in these cancers. As our cohort (n = 16) was 
quite small, a larger study with more samples needs to be performed with the use of tumour 
biopsies to conclusively reveal whether AID is associated with these cancers.  
 
Mass spectrometry data generated from a large set of colon cancer samples in Professor 
Blackburn laboratory at the University of Cape Town was analysed for AID expression. The 
two cohorts were comprised of normal and tumour biopsies in a colorectal cancer (CRC) 
cohort (n = 18) and from the Jorissen cohort (n = 155) (Jorissen et al., 2008). These cohorts 
were classified according to two distinct sub-types, the one being immune suppressive and 
the other inflammatory in nature. The analysis found that AID was weakly downregulated in 
the inflammatory sub-type of the CRC cohort (fold change of -1.6 and a false discovery rate 
of 0.00067), with no differential expression observed in the Jorissen cohort or between the 
tumour versus normal biopsy analysed (unpublished data (2015), with thanks to Katie Viljoen 
and Professor Jonathan Blackburn, University of Cape Town). These results correlate with the 
mRNA and qPCR results described in this chapter, reiterating that AID overexpression is more 
pertinent to B-cell derived cancers, such as Burkitt’s lymphoma. Therefore, developing an 
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epithelial derived AID overexpressing model to study the role of AID in cancer was deemed 
irrelevant.  
 
From the results in this chapter, we were able to confirm that AID is expressed in 
lymphoblastoid cells, with increased expression in the BL cell lines thus confirming the 
association of AID with these cancers. Furthermore, the L1439A cell line was identified as a 




Chapter 4: Ectopic overexpression of AID in the B Lymphoblastoid Cell Lines 
4.1 Introduction 
AID overexpression has been associated with the development of B-cell lymphomas, 
especially Burkitt’s lymphoma (BL) (Robianni and Nussenzweig, 2013). Additionally, various 
reports have indicated that it may also contribute to the transformation of cells of non-
lymphoid origin, such as epithelial cells of the gastro intestinal tract (GIT) and prostate 
(Matsumoto et al., 2007; Lin et al., 2009). However its exact function in the oncogenic process 
is not well defined. This project aims to use overexpression cell models to better define the 
oncogenic function of AID. In the previous chapter AID expression was not detected in the 
sixteen cell lines (14 cancer and 2 normal cell lines) of epithelial origin, while its 
overexpression was confirmed in BL cells. Thus this chapter focuses on the overexpression of 
AID in a B-cell line model.  
 
The use of overexpression cell lines as models are useful in studying the role of specific factors 
in the mechanisms of disease and oncogenic development (Prelich, 2012). Unlike other model 
organisms where direct genetic manipulation can be performed (eg. transgenic mice models), 
genetic alterations to humans need to be performed indirectly using cell culture models. With 
induced overexpression of the gene of interest (AID) in a cell line with relatively low 
expression levels, comparison of phenotypic and molecular changes between the control and 
overexpressing models allow for the elucidation of possible mechanistic pathways. Thus with 
the aim to better define the role of AID in oncogenesis, the development of a cell line of B-
cell origin ectopically overexpressing AID was undertaken and the process reported in this 
chapter. As will become clear in the sections which follow, an AID overexpressing model 
proved not to be ideal for studying its oncogenic function due to the highly mutagenic nature 
of this enzyme. The results of this overexpression study are described in detail below.  
 
4.2 Results 
4.2.1 Analysis of the mammalian expression plasmids that constitutively express AID 
Two plasmids were utilised in this study, the pEGFP-N3 and pcDNA-3.1 backbones which 
each contained the AICDA gene. The identification of pEGFP-N3-AID and pEGFP-N3-Empty 
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plasmids were verified by restriction digests using NotI and EcoRI, based on the available 
plasmid map (Appendix C, Figure C1). Figure 4.1 below shows the three plasmid 
conformations of the uncut plasmids, namely the supercoiled, linear and nicked circular 
conformations. While the cut plasmids using the above mentioned enzymes produced two 
fragments; 4.7 kb and 767 bp fragments for the pEGFP-N3-AID plasmid, and 3.9 kb and 767 
bp fragments for the pEGFP-N3-Empty plasmid. 
 
Figure 4.1: Restriction enzyme digestion of the pEGFP-N3-AID and pEGFP-N3-Empty plasmids. Lanes 
1 to 5 are as follows: pEGFP-N3-Empty cut with NotI and EcoRI, pEGFP-N3-Empty uncut, GeneRuler™ 
1 kb DNA Ladder (Thermo Scientific™, US), pEGFP-N3-AID cut with NotI and EcoRI and pEGFP-N3-AID 
uncut. These samples were electrophoresed on a 1 % agarose gel. 
 
The pEGFP-N3-AID plasmid then underwent Sanger sequencing (Inqaba Biotec, SA) to verify 
that the AICDA gene was cloned in frame with the EGFP tag, which is located downstream  of 
the AID coding region. Figure 4.2 shows the AICDA gene was cloned at 65 bp from the primer 
binding site and after analyses both AID and GFP were shown to be in-frame. Sequencing 
information and restriction digest information for the pcDNA-3.1-AID plasmid was already 







Figure 4.2: DNA electropherogram of pEGFP-N3-AID. The AICDA coding region is 597 bp long and 
shown to be cloned in-frame with the EGFP tag. The GFP selection cassette was also shown to be 
cloned in-frame.  Base pairs are written in black with the restriction enzyme sites from the plasmid 
map (Appendix C, Figure C1). 
 
To confirm AID protein expression from these plasmids, the COS-7 African green monkey 
kidney fibroblast cell line, which has relatively high transfection efficiency, was transfected 
with either pEGFP-N3-AID or pcDNA-3.1-AID, as well as their respective controls (Section 
2.11). Table XIII below shows concentrations and purity of the plasmids as determined by the 
NanoDrop™ ND-1000 (Thermo Scientific™, US), following large scale isolation, performed 
previously and already available in this laboratory, using the PureYield™ Plasmid Maxiprep 
System (Promega, US) which ensured the removal of endotoxins (a bacterial contaminant 
which can interfere with transfection). An amount of 300 ng of each plasmid was transfected 
and total protein was isolated approximately 30 hours later using the boiling blue method 
(Section 2.7.3).  
 
Table XIII: Concentrations of the plasmids following isolation. 
 Concentration (µg/µl) 260/230 Ratio 
pEGFP-N3-AID 308.50 1.88 
pEGFP-N3-Empty 379.40 1.87 
pcDNA-3.1-AID 419.10 1.88 




Integrity of plasmids was shown to be intact with no degradation as determined by gel 
electrophoresis (data not shown). A volume of 5 µl of each protein extract was subjected to 
SDS-PAGE and western blotting using an antibody specific to AID (Invitrogen, US). Figure 4.3 
below shows the successful transfection of the COS-7 cells with each plasmid, as well as 
expression of the protein. Due to the EGFP tag, the band detected for the pEGFP-N3-AID 
plasmid is larger. As expected, no band was detected when cells were transfected with the 
empty plasmid.  
 
Figure 4.3: Western blot analysis of COS-7 cells transfected with plasmids. COS-7 cells transfected 
with the empty plasmids (pcDNA-3.1-Empty and pEGFP-N3-Empty) do not express AID, as is expected 
while cells transfected with the two plasmids which contain the AICDA coding sequence (pcDNA-3.1-
AID and pEGFP-N3-AID) produce easily detectable levels of AID protein. The band detected in cells 
transfected with the pEGFP-N3-AID plasmid is larger due to the EGFP tag. 5 µl of protein in 2X boiling 
blue buffer was boiled at 95 °C for 10 minutes before being loaded and separated on a 12 % SDS-PAGE 
gel at 100 V for 200 minutes in 1X running buffer. The protein was then transferred onto a 
nitrocellulose membrane (Bio-Rad) for 75 minutes at 100 V in 1X transfer buffer. This was then 
detected using the Clarity™ Western ECL Substrate (Bio-Rad). To detect AID, mouse anti-AID 
(Invitrogen) was used, with a HRP bound goat anti-mouse secondary antibody (Bio-Rad).  
 
4.2.2 The L1439A cell line is recalcitrant to conventional transfection techniques 
4.2.2.1 Cell density and optimisation 
The L1439A cell line has a relatively long doubling time and requires double the amount of 
FBS (20 %) for survival, compared to most other cell lines. The optimal growth conditions and 
cell density to be used for transfection needed to be determined before the experiment was 
attempted. The characteristics of a healthy L1439A cell population are mostly large, compact, 
circular shaped clumps, with fewer smaller clumps, and some single cells floating in the 
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medium (Figure 4.4). Using guidelines from transfection protocols, cells were seeded at 
various densities (1 x 105 cells per well, 2 x 105 cells per well, 3 x 105 cells per well, 6 x 105 cells 
per well, 8 x 105 cells per well and 1 x 106 cells per well) in a six-well plate (35 mm) and 
monitored daily using the light microscope over a period of seven days. Figure 4.4 shows the 
appearance of the cells seven days post plating and based on this observation, the 
concentration of 8 x 105 cells per well in a six-well plate was chosen as a reasonable density 
for transfection. This is because for optimal transfection, protocols recommend that cells are 
between 60 – 80 % confluent.  
 
 
Figure 4.4: Various densities of L1439A cells in culture seven days post plating. L1439A was seeded 
at 1 x 105 (A) 2 x 105 (B) 3 x 105 (C) 6 x 105 (D), 8 x 105(E), 1 x 106 (F) in a six-well plate (35 mm) and 
after seven days visualised under the light microscope. Healthy L1439A cells are characterised as 
compact, circular clumps in combination with scattered single cells. Scale bars are in white. 
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4.2.2.2 Kill curve for L1439A using G418 
Stable transfection requires the integration into the genome of the gene of interest and 
selection pressure, usually in the form of an antibiotic, for transformed clones which express 
a gene conferring resistance to the antibiotic. Both of the plasmids used in this study contain 
the neomycin resistance gene, which confers a resistance to the aminoglycoside antibiotic 
Geneticin (G418). Most cells, including L1439A are sensitive to G418, thus only successfully 
transfected cells will be able to survive and proliferate in the presence of this antibiotic. 
Different cell lines and cell types have different levels of susceptibility to G418, thus with no 
published data on the susceptibility of L1439A to G418, the concentration of G418 to use to 
kill all untransformed cells over a period of five to seven days needed to be determined. A 
range of cell densities were plated (1 x 105 cells per well, 2 x 105 cells per well, 3 x 105 cells 
per well, 4 x 105 cells per well, 5 x 105 cells per well and 1 x 106 cells per well) in a 96-well 
plate and observed for seven days to assess the optimal density to use for developing the kill 
curve. A cell density of 1 x 105 cells per well was found to be the most appropriate. The cell 
density was used to generate the kill curve using the WST-1 assay to measure cell viability 
over seven days (Section 2.12.2). The result are shown in Figure 4.5 and a concentration of 
800 µg/ml of G418 was selected.   
 
Figure 4.5: Kill curve of L1439A using G418. L1439A cells were seeded at a density of 1 x 105 cells per 
well in a 96-well plate. Varying concentrations of G418 was added to each well, 400-, 500-, 600-, 700-
, 800-, 900-, 1000 µg/ml, and cell  viability was determined using the WST-1 proliferation assay. Each 
sample was performed in triplicate. All samples were normalised against the untreated cells (0 µg/ml).     
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4.2.2.3 Lipid- and polymer-based transfection  
B lymphoblast cell lines are known to be notoriously difficult to transfect using conventional 
techniques (Maurisse et al, 2010). Nevertheless, the lipid-based transfection reagent, X-
tremeGENE HP (Roche, Germany), which was relatively new on the market, was used in an 
attempt to transfect L1439A. This lipid-based transfection reagent causes the genetic 
material, in this case plasmid DNA, to enter the cell by forming a vesicle around the DNA which 
merges with the cell membrane as both are composed of a phospholipid bilayer. Finding the 
optimum amount of transfection reagent to use is important, as too much can be toxic to cells 
and compromise the experiment. The cells were exposed to four different concentrations of 
the reagent (1 %, 2 %, 3 % and 4 %) and after 30 hours, cell viability in the presence of this 
reagent was determined using the WST-1 Assay (Section 2.12.1). In addition, the optimal time 
post-addition of the WST-1 reagent was determined using four different time points (0.5 
hours, 1 hour, 2 hours and 4 hours). From the result presented in Figure 4.6 below, 3 % of X-
tremeGENE HP was chosen since this volume was the highest that could be used without 
causing cell death. In addition, the WST-1 incubation time of two hours was selected as the 
optimal time point in which analyse the results on the GloMax®-Multi microplate reader 






Figure 4.6: Determination of optimal X-tremeGENE HP concentration for transfection of L1439A 
cells. Four different concentrations of transfection reagent were added to the L1439A cells and 
incubated for 30 hours, the WST-1 reagent was added and analysed at different time intervals over 
four hours (0.5 hours, 1 hour, 2 hours and 4 hours). A transfection reagent concentration of 3 % and 
a WST-1 incubation time of two hours was selected, as this had a low amount of cell death while 
maintaining a high effective concentration. SEM values are represented by the error bars. 
 
4.2.2.4 Transfection of L1439A 
The L1439A cells were therefore transfected with the pEGFP-N3-AID and pEGFP-N3-Empty 
plasmids using 3 % X-tremeGENE HP (Roche, Germany). This plasmid was used due to the 
presence of the EGFP tag which allows easy detection of transfected cells using fluorescence 
microscopy. After an incubation period of 30 hours post-transfection, no successfully 
transfected cells were detectable (Figure 4.7; A-F). To verify the integrity of the transfection 
reagent, the human fibrosarcoma cell line HT-1080, which is an established, easily 
transfectable cell line, was transfected in parallel with the same plasmid. As can be seen in 
Figure 4.7 below, numerous HT-1080 cells were positive for GFP (Figure 4.7; G-L). This 






Figure 4.7: Fluorescence microscopy images of L1439A and HT-1080 cells following transfection with 
pEGFP-N3-Empty and pEGFP-N3-AID using X-tremeGENE HP. Cells were transfected with either the 
pEGFP-N3-AID or pEGFP-N3-Empty, incubated for 30 hours, and visualised using a fluorescent 
microscope. A-C is the L1439A cells transfected with pEGFP-N3-Empty and D-F are the L1439A cells 
transfected with pEGFP-N3-AID. G-I are the HT-1080 cells transfected with pEFGP-N3-Empty and J-L 
are the HT-1080 cells transfected with the ePGFP-N3-AID plasmid. LHS panels represent the overlaid 
fluorescent and phase contrast images, the middle panels represent the fluorescent images, while the 
RHS panels represent the phase contrast images. Scale bars are in white.   
 
As an alternative option, a cationic polymer-based transfection reagent called TurboFect 
(Thermo Scientific™, US), recommended by the manufacturer for “difficult-to-transfect” cell 
lines was used. This reagent functions by forming a compact, positively charged complex 
between the DNA and the polymers, this complex then protects the DNA from degradation 
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and allows the plasmid to be delivered into the cells. Unfortunately, as with the lipid-based 
transfection reagent, we were unable to successfully transfect L1439A with this reagent (data 
not shown). Since chemical transfection was ineffective with L1439A, electroporation was the 
next recommended course of action in overexpressing AID in these cells.  
 
4.2.4 Nucleofection 
Electroporation is a process whereby the cells are subjected to an electric shock. The Amaxa™ 
Nucleofector II™ (Lonza, Germany) machine was used, with the recommended Amaxa® Cell 
Line Nucleofector® Kit V (Lonza, Germany). This system produces an electroporatic shock 
creating pores in the cell membrane, and with the help of the nucleofector solution (a 
proprietary solution made up of solutes) which protects the cells while carrying the electric 
charge, allowing the plasmids to enter the cells. This technique is generally quite harmful to 
cells, and thus a protocol needed to be optimised for the L1439A cell line. Following 
consultation with the Lonza Technical team in Germany, a list of five nucleofection 
programmes were recommended, of which we were required to identify one which produced 
good transfection efficiency without too much cell death. It is important to note that the 
L1439A cells are extremely sensitive to even small changes to their growth conditions and to 
stress. They are also highly dependent on growth factors, and grow best in their own 
conditioned medium.  
 
4.2.4.1 Programme optimisation for the nucleofection of L1439A cells using a control GFP-
expressing plasmid  
The L1439A cells were subjected to nucleofection with the pmaxGFP™ plasmid provided in 
the nucleofector kit, using five different programmes recommended by the Lonza Team listed 
in Section 2.13. Due to the growth requirements of these cells, a mixture of fresh and 
conditioned media was added post-nucleofection in an attempt to promote cell survival 
following this harsh treatment. After 48 hours post-nucleofection, the cells were visualised 
using a fluorescent microscope to identify cells which had taken up the pmaxGFP™ plasmid. 
Figure 4.8 below shows the results for the three most successful programmes. A control 
consisted of cells which underwent nucleofection without inclusion of a plasmid. Of the five 
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programmes used, X-001 was selected as the most effective, as a greater number of GFP 
positive cells were visible, with the least cell death observed at that time point.  
 
Figure 4.8: Fluorescence microscopy images of nucleofected L1439A cells with the pmaxGFP™ 
control plasmid. Cells were nucleofected with the GFP-tagged plasmid provided in the nucleofection 
kit. LHS panel represent the fluorescent images, while the RHS panel are the phase contrast images. 
A-B are the control cells which did not contain any plasmids, C-D are using programme X-001, E-F are 
using programme P-016 and G-H are using programme T-020. Scale bars are in white.   
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4.2.4.2 Nucleofection of the L1439A for AID overexpression 
Using the programme X-001, the L1439A cells were subjected to nucleofection using the 
pEGFP-N3-Empty, pEGFP-N3-AID, pcDNA-3.1-Empty and pcDNA-3.1-AID plasmids. Two sets 
of plasmids were used as the EGFP tag could interfere with the cellular function of AID, thus 
using a second plasmid in parallel would confirm the EGFP tagged plasmid results. Forty-eight 
hours post-nucleofection G418 was added at a concentration of 800 µg/µl to start selecting 
for positive transformants. Fresh antibiotic (75 % of determined concentration) was added to 
the medium every 48 hours as G418 is heat labile and is reported to be degraded over time 
(Adolph, 1996). A gradual decrease in the viability of the cells was observed over the seven 
days post-nucleofection, with 100 % cell death being achieved at day seven. It was thought 
that this could be due to either the nucleofection process, or the added stress of the G418 
antibiotic selection. Therefore, the nucleofection experiment was repeated with the pEGFP-
N3 plasmid and a non-plasmid control without the addition of G418 and observed over seven 
days. Even without the antibiotic selection, the L1439A cells still did not survive. We therefore 
concluded that these fragile cells were not suitable for the electroporation process and were 
therefore not suitable as a cell culture model to study the role of AID.  
 
An alternative cell line was therefore selected for the overexpression of AID. Out of the panel 
of BL cell lines which were assessed for AID expression by western blot analysis (Figure 3.9 in 
Chapter 3), the Ramos cell line had relatively low AID expression (approximately 1.5 fold 
higher AID expression than the L1439A cells) and was therefore selected. Additionally, Ramos 
is a well characterised cell line which was compatible with the Nucleofector Kit V (Lonza, 
Germany) and had published nucleofector programmes, thus eliminating the need for time 
consuming and costly optimisation. The sections below describe the results obtained for the 
overexpression of AID in Ramos.  
 
4.2.4.3 Nucleofection of Ramos cells 
The literature suggests that the nucleofection programme O-006 is suitable for Ramos cells 
(Thapa et al., 2011). Similarly, the concentration of G418 antibiotic to use for the selection of 
transfected clones was also published at 1 000 µg/ml (Vaughan et al., 2014). Nucleofection 
was performed on the Ramos cells using both the pEGFP-N3 (empty as well as AID expressing) 
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and pcDNA-3.1 plasmids (empty as well as AID expressing) with G418 added 48 hours post-
nucleofection. The G418 was initially added at a concentration of 1 000 µg/ml and every 48 
hours, 75 % of the concentration of G418 was replenished due to the unstable nature of the 
chemical. The cells were expanded in culture for approximately two weeks before undergoing 
cell sorting to separate viable cells from dead cells. The Ramos cells nucleofected with the 
pEGFP-N3 plasmid were sorted using a fluorescent channel using the GFP tag as a means to 
identify viable cells. On the other hand, Ramos cells nucleofected with the pcDNA-3.1 plasmid, 
which does not express GFP, were sorted through the addition of 7-AAD, a DNA intercalating 
dye which binds to all exposed DNA and cannot cross the intact viable cell membrane. Thus 
7-AAD stains dead or dying cells which usually have punctured cell membranes, allowing entry 
of the 7-AAD stain which then binds to the DNA. Figure 4.9 illustrates diagrams which depict 
the cell sorting result. The control cells (A-C) which underwent the nucleofection process but 
without including any plasmid, are therefore not expected to display any fluorescence, as is 
the case (RHS panel). The pre-sort analysis of the cells nucleofected with the pEGFP-N3-Empty 
(D-F) show some GFP positive cells (approximately 2.6 % of the parent population), as can be 
seen by the cell population in blue in P2 (E) and the peak in P3 (F). After sorting, the cell 
population was checked for purity (G-I) as can be seen in panel I, the majority of the sorted 
cells were positive for GFP. However, no GFP positive cells could be detected within the 
Ramos cell population nucleofected with the pEFGP-N3-AID (J-L). The cell sorting results of 
Ramos cells nucleofected with pcDNA-3.1 plasmids were similar to what was observed for the 
pEFGP-N3 plasmids (Figure 4.10). While cells harbouring the pcDNA-3.1-Empty vector (D-I) 




Figure 4.9: Cell sorting analysis of the pEGFP-N3 plasmid transfected Ramos cells. The LHS panel 
represents the flow cytometric analysis of the forward and side scatter of the cells, the middle panel 
is the quadrants of expression where P2 represents the live GFP expressing cells, the RHS panel is a 
histogram analysis of the GFP expression where anything that falls within the P3 quadrant are positive 
for GFP expression. A-C are the control cells which underwent nucleofection, but contained no 
plasmid, D-F are the cells nucleofected with pEGFP-N3-Empty before the sorting, G-I are the sorted 






Figure 4.10: Cell sorting analysis of the pcDNA-3.1 plasmid transfected Ramos cells. The LHS panel 
represents the flow cytometric analysis of the forward and side scatter of the cells, the middle panel 
is the quadrants of expression where Q3 represents the live cells, the RHS panel is a histogram analysis 
of the 7-AAD expression. A-C are the control cells which underwent nucleofection, but contained no 
plasmid, D-F are the cells nucleofected with pcDNA-3.1-Empty before the sorting, G-I are the sorted 
cells from D-F and a check of the purity of the sort, while J-L are the cells nucleofected with pcDNA-
3.1-AID as seen before sorting, M-O are the sorted cells from J-L and a check of the purity of the sorted 
cells.  
 
From the above results, it would appear that it is the constitutive and relatively abundant 
expression of AID which is causing cell death. The nucleofection experiment was repeated 
using the pEGFP-N3 plasmids and GFP expression was monitored by flow cytometry earlier 
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than in the previous experiment, at day three, to determine how long the AID-expressing cells 
were able to stay viable before death. This revealed that the majority of cell death occurred 
three days post-nucleofection, with no further detection of GFP expression within the cell 
population (Figure B8). Therefore, the deleterious cellular effects of AID overexpression are 
rapid. 
  
4.2.5 Mechanism of cell death by AID overexpression 
In this section, we aimed to ascertain whether the AID-induced cell death observed in the 
Ramos cells was via senescence or apoptosis. These are the main two possible mechanisms 
of cell death usually brought about by overexpression of an oncogene. In the case of 
senescence, cells usually stop dividing, acquire a typically large morphology, and eventually 
disintegrate. Apoptosis on the other hand is a form of programmed cell death.  
 
4.2.5.1 SA-β-Gal activity 
To detect whether AID led to senescence, a senescence-associated β-galactosidase (SA-β-gal) 
assay was performed (Section 2.15). Cells undergoing senescence produce a biomarker called 
β-galactosidase (β-gal) at pH 6.0, which is not produced in healthy cells (Lee et al., 2006). In 
the presence of β-gal, a chromogenic substance such as X-gal can be cleaved and used to 
detect senescence. The AID overexpressing cells were subjected to X-gal and the cells 
undergoing senescence produced a blue colour which was visualised and counted on the 
haemocytometer under the microscope. Figure 4.11 is a graphical comparison between the 
AID expressing and empty pEGFP-N3 vectors compared to a control plasmid which 
constitutively expresses β-gal (pCMV-β-gal – kindly donated by Associate Professor Prince, 
Cell Biology, University of Cape Town). The cells transfected with the control pCMV-β-gal 
plasmid had a positive β-gal expression of approximately 93 %, while both the Ramos cells 
nucleofected with AID-expressing and empty vectors had a significantly lower, but similar 
expression of approximately 65 %. This is contrary to the difference in cell death experienced 
by each nucleofected sample as the AID overexpressing cells had been shown to have a much 
higher cell death than cells nucleofected with the empty vector. Nevertheless, since no 
difference in viability could be observed between empty vector and AID-expressing cell, it can 
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Figure 4.11: Expression of X-gal between different nucleofected plasmids in SA-β-gal assay. Each bar 
represents the expression of β-gal with the blue and red bar representing cells undergoing 
senescence. The blue (pEGFP-N3-Empty) and the red (pEGFP-N3-AID) bar are the nucleofected Ramos 
cells, the green (pCMV-β-gal) bar represents cells nucleofected with a plasmid which constitutively 
expresses β-gal. **** represents a p value of < 0.0001 (Prism 6, GraphPad, US).  
 
4.2.5.2 Cell cycle profiling 
Cells that have sustained an injury, whether mechanical or genomic (as is the case in this 
study), may undergo a process of programmed cell death to protect the organism. Cell cycle 
profiling was used as an initial method to determine whether apoptosis is occurring. Cell cycle 
profiling uses the measure of DNA content to determine the proportion of cells in the various 
phases of the cell cycle. Cells in the G0/G1 phase will have N amount of DNA, while cells in 
the G2 phase will have 2N amount of DNA. Cells in the S phase, which are undergoing DNA 
replication, have DNA content between N and 2N. This method has the ability to also detect 
cells containing fragmented DNA, in the form of sub-G1 peak, which are usually indicative of 
apoptotic cells. Figure 4.12 below represents the cell cycle profiling of the Ramos cells 
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nucleofected with the pEGFP-N3 plasmids. The Ramos cells nucleofected with pEGFP-N3-
Empty (A) has 22.69 % apoptotic cells, however, there is a population of healthy looking cells 
(77.31 %) which display a normal cell cycle profile. The Ramos cells nucleofected with the 
pEGFP-N3-AID plasmid has a lot more apoptotic cells as depicted by a large sub-G1 peak which 
is merging with the G1 peak, and no distinct S phase or G2 phase cells can be seen. This shows 
that the majority of cells in this population have fragmented DNA, indicative of apoptosis.  
 
 
Figure 4.12: Cell cycle profiling of the nucleofected Ramos cells. A is the cell cycle profile of Ramos 
cells nucleofected with pEGFP-N3-Empty, B and C depict the cells which were selected for the profiling. 
D is the cell cycle profile of Ramos cells nucleofected with pEGFP-N3-AID, E and F are the cells which 
were selected for the profiling. The sub-G1 peaks, in blue, represent cells with fragmented DNA, 
indicative of apoptosis.  
 
4.2.5.3 Apoptosis 
To determine whether the cells overexpressing AID were undergoing apoptosis, the Annexin 
V Kit (BD, UK) (Section 2.16) was used. This kit contained a fluorescently tagged Annexin V 
antibody that binds to cells undergoing apoptosis. As can be seen in Figure 4.13 below, Ramos 
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cells nucleofected with the pEGFP-N3-Empty vector had 19.24 % of the cells positive for 
Annexin V (A), while the pEGFP-N3-AID cells were 51.49 % positive (B), showing that more of 
the cells overexpressing AID were undergoing apoptosis..  
 
Figure 4.13: Flow cytometric analysis of Annexin V for the nucleofected Ramos cells. (A) is the 
Annexin V expression profile of pEGFP-N3-Empty and (B) is the Annexin V expression profile of pEGFP-
N3-AID. The values in each block represent the percent of cells counted.    
 
4.3 Discussion and conclusion 
Results from the previous chapter indicated that the EBV-immortalised B lymphoblastoid cell 
line, L1439A, would be a potentially good model to use for the ectopic expression of AID to 
study its oncogenic function. To achieve ectopic expression, mammalian plasmids 
constitutively expressing AID were obtained and needed to be verified. Two different plasmid 
sets were available for use in this study, and both were found to express the AID protein when 




The optimal culture conditions and cell line maintenance of L1439A had to be determined 
prior to introducing AID ectopically (Figure 4.4). This cell line which was created at the 
University of Cape Town, had not been used by many researchers, and information about the 
optimal culture conditions were mostly anecdotal. Furthermore, no protocols were available 
for the introduction of a plasmid into these cells. As these cells were taken from a healthy 
donor, and then immortalised using EBV, it had a relatively slow growth rate and required 
high concentrations of growth factors (20 % FBS) to grow efficiently. These cells also prefer 
conditioned culture medium, since a decrease in cell density led to growth arrest and cell 
death. In this study, it was established that the optimal cell number for healthy growth was 
seeding 8 x 105 cells per ml in a six-well plate (35 mm), and at this confluency, cells grew well 
over a period of seven days, during which time experimental procedures could be carried out.  
Transfection reagents are known to elicit a cytotoxic response in cells, thus a balance needs 
to be established for efficient transfection with low toxicity. The WST-1 assay was used to 
determine the efficient transfection concentration to use for the lipid- and polymer-based 
transfection reagents. This experiment had two objectives, to identify the ideal concentration 
of transfection reagent, while at the same time determining the best incubation time for the 
WST-1 reagent (Figure 4.6). Two hours was selected as the optimal WST-1 incubation time as 
the four hour reading approached the absorbance saturation levels detectable by the Glo-
Max®-Multi+ multiplate reader (Promega, US) and thus would have decreased the assay’s 
sensitivity. The concentration of 3 % was selected for the transfection reagent as it 
maintained the same toxicity levels as the lower concentrations, as toxicity increased with 
higher transfection reagent concentrations. This value maintained a high enough 
concentration of transfection reagent for greater transfection efficiency, while maintaining 
low enough cytotoxicity so as to prevent cell death.  
 
A concentration of 800 µg per ml of the antibiotic G418 was found to be optimal for the 
selection of positive transfectants as this concentration killed the majority of cells after seven 
days (Figure 4.5). It can be noted here that generating the kill curve required many attempts, 
since the control cells that were used for normalisation were not subjected to G418 selection, 
became over-confluent prior to the endpoint of the experiment. A fine balance exists 
between too few and too many cells: too few means the cells do not grow; too many means 
the cells become confluent too soon. Thus several attempts were made, with various cell 
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densities at the start of the experiment, in order to reach a satisfactory result. The particularly 
demanding growth requirements of these cells made a seemingly simple process 
complicated. However, this hurdle was eventually successfully overcome.  
 
The literature indicated that B lymphoblastoid cells are notoriously difficult to transfect 
(Maurisse et al., 2010; Potter and Heller, 2010), however, with several new transfection 
reagents on the market claiming to transfect “difficult-to-transfect” cell lines, we first 
attempted conventional transfection using two of these lipid- and polymer-based reagents 
(Figure 4.7). However, these did not prove successful for the L1439A cells and thus the 
Amaxa® Nucleofector™ II (Lonza, Germany) machine was selected. The nucleofection process 
required significant optimisation, which was performed with assistance from the Lonza 
technicians in Germany, and a low level of nucleofection was achieved using one of the 
suggested programmes (Figure 4.8).  
 
However, this process proved detrimental to these cells which did not survive post-
nucleofection, even when no plasmids were transfected into them. While this system has 
been used successfully in published reports for EBV-immortalised B lymphocyte cell lines 
(Choi et al., 2011), it did not work in our hands. A possible explanation may be the cell line 
itself since EBV has the ability to integrate in many different locations in the genome, this 
results in a high level of heterogeneity among various clones. Future attempts could focus on 
sourcing a different clone from the same source, or purchasing a cell line in which a 
nucleofection protocol has been tried and tested successfully. Alternatively, a different 
nucleofector could be used, for instance, the Neon® system from Thermo Scientific (US), 
which seems to have been used with some success by other researchers (unpublished report; 
informal discussion). The Neon® Transfection System (Thermo Scientific, US) requires less 
cells and has been shown to successfully transfect other lymphoblast cells, such as the BL  cell 
line P3HR1, which has similar growth requirements to L1439A (Cancian et al., 2011).  
 
As an alternative to L1439A, the BL cell line Ramos was selected as a model of AID 
overexpression due to its relatively low AID protein expression compared to the other BL cell 
lines which were screened in this study. This is a well characterised cell line for which much 
of the optimal nucleofection conditions and G418 selection information is available in 
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published reports (Thapa et al., 2011; Vaughan et al., 2014). Using these conditions, the 
Ramos cells were successfully nucleofected with both of the AID overexpressing plasmids, as 
well as their respective empty control plasmids. However, it soon became clear that cells 
which expressed AID had a definite growth disadvantage. Cells containing the empty vector 
could be selected by flow cytometry and expanded well in culture, while cells overexpressing 
AID did not survive (Figures 4.9 and 4.10). This was confirmed when the experiment was 
repeated, and even with reduced selection and expansion periods, AID overexpressing cells 
still died. We therefore propose that the highly mutagenic nature of AID lead to significant 
cellular damage, triggering the cell stress pathway leading to cell death. This was found to 
occur mostly by apoptosis, as demonstrated by Annexin V incorporation (Figure 4.13). 
Although Ramos already has high AID expression compared to a normal B-cell line, it is likely 
that this cancer cell line, has some but not all checkpoints compromised. Even though Ramos 
can tolerate a certain level of genomic instability, this cell line has a threshold which was 
breached when AID was overexpressed, triggering DNA damage checkpoints leading to 
apoptosis.  
 
One of the main drivers of apoptosis is the tumour suppressor transcription factor p53. Since 
cancers need to evade apoptosis, it is not surprising that approximately 50 % of all human 
cancers have a mutated form of p53 (Wang et al., 2011). The normal function of wild-type 
p53 is to promote senescence, inhibit cell cycle progression and induce apoptosis (Freed-
Pastor and Prives, 2012). However, when this gene is mutated, it not only loses its tumour 
suppressor function, the mutated p53 forms complexes with proteins which further repressor 
cellular function (Freed-Pastor and Prives, 2012). In previous studies, Wang et al. (2011) were 
unable to detect functional or even a mutated form of p53 in Ramos and thus classified this 
cell line as p53 deficient, however, further studies have revealed that Ramos does contain 
mutant p53 (Farrell et al., 1991; O’Connor et al., 1993; Nazari et al., 2011). Wang et al. (2011) 
showed that the mutant form of p53 in Ramos cells still maintains some function (ability to 
translocate to the mitochondria), but has no effect on apoptosis. It is therefore likely that the 
apoptosis observed in this study is independent of p53 (Fulda and Debatin, 2006; Elmore, 
2007).  The most likely cause of apoptosis in the AID overexpressing cells resulted from AID’s 
ability to cause double strand DNA (dsDNA) breaks, thus accumulating genetic alterations and 
creating genome instability which then induced apoptosis. An alternative mechanism of cell 
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death could be the intrinsic apoptotic pathway which has been shown to be independent of 
p53 (Fulda and Debatin, 2006; Elmore, 2007).  
 
In future studies, the use of a plasmid with an inducible promotor, as opposed to the 
constitutively active one which was used here, could be more successful. An inducible 
promotor will allow time for the cells to be nucleofected, selected and expanded as required, 
before the AID expression is induced. However, it is likely that the outcome would be the 
same, i.e., that the cells will undergo apoptosis once AID expression reaches a certain level 
within the cells which cannot be tolerated.  
 
An alternative approach was adopted for studying the function of AID in the oncogenic 
process; the use of a knockdown model. This was performed in the Ramos cell line and the 







Chapter 5: Knockdown of AID Expression in the Burkitt’s Lymphoma Cell Line 
Ramos Using siRNA 
5.1 Introduction 
As demonstrated in the AID-overexpression study (Chapter 4), high expression levels of AID 
can be deleterious to cells, thus highlighting why this enzyme is under such tight regulation 
under normal conditions (Zan and Casali, 2013). With the cells unable to propagate post-
electroporation, we could not study the downstream effects of AID overexpression as a 
means to study AID’s role in oncogenesis. As an alternative, a knockdown approach was 
adopted. This was done using siRNAs which specifically target AID mRNA for degradation, 
thereby reducing the AID protein expression. As a control, a scrambled siRNA was used, which 
did not target any known sequences in human cells. The cell line Ramos, which is a Burkitt’s 
lymphoma (BL) cell line, was selected for AID knockdown as it had relatively low AID 
overexpression compared to the other BL cell lines and closer expression levels to the normal 
EBV-immortalised human B lymphoblastoid cell line, L1439A (Figures 3.5 and 3.9). The Ramos 
cell line has been extensively researched upon and thus the optimal cell densities and 
knockdown protocols had been established. This chapter presents the results of the cellular 
effects observed in cells where AID was knocked down, relative to control cells, and particular 
effects were measured which relate to carcinogenesis. These include cell proliferation and 
viability, migration, genome integrity, B-cell phenotype (CD marker expression) and sensitivity 
to a chemotherapeutic drug.  
 
5.2 Results 
5.2.1 Identification of the most effective siRNA and knockdown conditions to be used in this 
study 
Since no validated siRNA for AID were available, a pack of four siRNAs, each targeting a 
different region of the AID mRNA, which putatively targeted AID was purchased (Qiagen, 
Germany) and each one was tested for its effectiveness in knocking down AID expression in 
the Ramos cell line. For this knockdown experiment, as with transfection of AID 
overexpressing plasmids described in Section 4.2.2.3, optimisation of conditions was required 
with regards to transfection reagent concentration and cell density. Kusao et al. (2012) 
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previously published their knockdown conditions of the Ramos cell line, which included the 
optimal cell density and plate format using Qiagen (Germany) siRNA. These guidelines were 
therefore followed, which entailed plating 1 x 105 cells per well in a 24-well plate format.  
 
5.2.1.1 Selection of transfection reagent 
The siRNA manufacturers recommended the use of the transfection reagent HiPerfect 
(Qiagen, Germany). This experiment was performed as outlined in Section 2.18.1 using either 
375 ng or 750 ng of each of the four siRNAs. Similarly, various concentrations of the HiPerfect 
transfection reagent was used, i.e. 3 µl or 6 µl per reaction as shown in Table XIV below.  
 
Table XIV: siRNA concentrations used in the optimisation reaction for each of the four 
siRNA.  
Concentration of siRNA 375 ng 375 ng 
Volume of HiPerfect Reagent 3 µl  6 µl 
Concentration of siRNA 750 ng 750 ng 
Volume of HiPerfect Reagent 3 µl 6 µl 
 
Following transfection, total protein was extracted using 2X boiling blue buffer (Section 2.7.3) 
and AID protein expression determined by SDS-PAGE followed by western blotting (Section 
2.8). Using these conditions, no effective knockdown of AID could be observed for any of the 




Figure 5.1: AID protein expression in BL cell line Ramos after transfection with AID siRNA using the 
transfection reagent HiPerfect. Western blot analysis displaying the protein expression levels of AID 
after these cells had been transfected with 375 ng and 750 ng of each of the four siRNA, using 3 µl or 
6 µl of HiPerfect (Qiagen, Germany) transfection reagent. Untreated Ramos cells were used as a 
comparison. 12 µl of protein in 2X boiling blue buffer was boiled at 95 °C for ten minutes before being 
loaded and separated on a 12 % SDS-PAGE gel at 100 V for 200 minutes in 1X running buffer. The 
protein was then transferred onto a nitrocellulose membrane (Bio-Rad) for 75 minutes at 100 V in 1X 
transfer buffer. This was then detected using the Clarity™ Western ECL Substrate (Bio-Rad). To detect 
AID, mouse anti-AID (Invitrogen, US) was used, with a HRP bound goat anti-mouse secondary antibody 
(Bio-Rad).  
 
The knockdown was then attempted using the X-tremeGENE HP (Roche, Germany) 
transfection reagent that was previously used in Section 4.2.2.4 following the methodology 
described in Section 2.18.2. In the initial attempt, 500 ng of each siRNA was used and AID-
siRNA3 showed significantly more knockdown with an 84 % reduction in AID protein 
expression compared to Ramos, as is shown in Figure 5.2 below. This siRNA was therefore 




Figure 5.2: AID protein expression in BL cell line Ramos after transfection with AID siRNA using 
transfection reagent X-tremeGene HP. (A) Western blot analysis displaying the protein expression 
levels of AID after these cells had been knocked down with 500 ng of each of the four siRNA. Untreated 
Ramos cells were used as a comparison. 12 µl of protein in 2X boiling blue buffer was boiled at 95 °C 
for ten minutes before being loaded and separated on a 12 % SDS-PAGE gel at 100 V for 200 minutes 
in 1X running buffer. The protein was then transferred onto a nitrocellulose membrane (Bio-Rad) for 
75 minutes at 100 V in 1X transfer buffer. This was then detected using the Clarity™ Western ECL 
Substrate (Bio-Rad). To detect AID, mouse anti-AID (Invitrogen) was used, with a HRP bound goat anti-
mouse secondary antibody (Bio-Rad). The p38 protein was used as a loading control and was detected 
using the rabbit anti-p38 antibody (Sigma-Aldrich) and the HRP bound goat anti-rabbit secondary 
antibody. (B) Densitometric analysis of the signal intensity of the bands analysed using the Li-Cor 
Image Studio Lite software (Version 4.0, Germany), and normalised to p38 and the Ramos control.  
 
5.2.1.2 Optimisation of AID knockdown using AID-siRNA3 
Once an effective siRNA was identified (AID-siRNA3), the most ideal concentration of the 
siRNA reagent to use for further experiments needed to be determined. A range of siRNA 
concentrations (500 ng, 750 ng, 1 000 ng and 1 250 ng) was therefore used in knockdown 
experiments, and a scrambled siRNA, at the same concentrations, was used as a negative 
control. Figure 5.3 below shows the AID knockdown using AID-siRNA3 versus the scrambled 
siRNA (siRNA Neg), for the two most effective concentrations of 1 000 ng and 1 250 ng. From 




Figure 5.3: Optimisation of AID-siRNA3 concentration for knockdown in the BL cell line Ramos. 
Western blot analysis displaying the protein expression levels of AID after these cells had been 
knocked down with 1000 ng and 1250 ng of AID-siRNA3 and scrambled siRNA (negative control). 12 µl 
of protein in 2X boiling blue buffer was boiled at 95 °C for ten minutes before being loaded and 
separated on a 12 % SDS-PAGE gel at 100 V for 200 minutes in 1X running buffer. The protein was then 
transferred onto a nitrocellulose membrane (Bio-Rad) for 75 minutes at 100V in 1X transfer buffer. 
This was then detected using the Clarity™ Western ECL Substrate (Bio-Rad). To detect AID, mouse anti-
AID (Invitrogen, US) was used, with a HRP bound goat anti-mouse secondary antibody (Bio-Rad). The 
p38 protein used as a loading control and detected using the rabbit anti-p38 antibody (Sigma-Aldrich) 
and the HRP bound goat anti-rabbit secondary antibody. 
 
5.2.2 Investigation of the effects of reduced AID expression in the Burkitt’s lymphoma cell 
line Ramos, compared to control cells 
Once AID could be knocked down reproducibly in Ramos cells, the resulting cellular effects 
could be measured. In each case, AID knockdown in the cells were confirmed by SDS-PAGE 
and western blotting (Section 2.8) to ensure that the observed effects were indeed caused by 






5.2.2.1 Assessment of genome integrity as measured by Phospho-Histone H2A.X (γ-H2AX) 
expression 
As described in Section 1.2.1, AID incorporates mutations in genomic DNA, which leads to 
dsDNA breaks through the DNA repair pathway (Zan and Casali, 2013). Through this pathway, 
certain factors are recruited to repair the dsDNA break site, one of these being the Phospho-
Histone H2A.X (Ser139) (γ-H2AX) protein (Kuo and Yang, 2008). We anticipated that the 
higher expression of AID in the Ramos cell line, relative to normal cells (Figures 3.5 and 3.9), 
maintains a certain level of dsDNA breaks, and hence phosphorylated γ-H2AX expression, and 
that this will be reduced when the level of AID is knocked down. After 48 hours post-
knockdown, total protein was isolated, separated by SDS-PAGE and phosphorylated γ-H2AX 
expression analysed by western blot analysis (Section 2.8). Figure 5.4 below clearly shows that 
compared to the Ramos cells transfected with the scrambled siRNA, as well as the untreated 
cells, no phosphorylated γ-H2AX protein could be detected in the AID knockdown cells. 
Confirmation of AID knockdown are shown on the right hand side of Figure 5.4.  
 
Figure 5.4: Phospho-Histone γ-H2AX protein expression levels in untreated, knockdown, and 
negative control Ramos cells. Western blot showing the expression levels of phosphorylated γ-H2AX 
between untreated Ramos cells, siRNA Neg and siRNA-AID3, with the respective knockdown 
confirmation western blot with the corresponding AID-siRNA3 and siRNA Neg samples on the RHS. 12 
µl of protein in 2X boiling blue buffer was boiled at 95 °C for ten minutes before being loaded and 
separated on a 15 % SDS-PAGE gel at 100 V for 180 minutes in 1X running buffer. The protein was then 
transferred onto a nitrocellulose membrane (Bio-Rad) for 75 minutes at 100V in 1X transfer buffer. 
This was then detected using the Clarity™ Western ECL Blotting Substrate (Bio-Rad). To detect 
phosphorylated γ-H2AX, rabbit anti-Phospho-Histone γ-H2AX (#2577, Cell Signalling, US) was used, 
with a HRP bound goat anti-rabbit secondary antibody (Bio-Rad). The p38 protein was used as a 
loading control and detected using the rabbit anti-p38 antibody (Sigma-Aldrich) and the HRP bound 
goat anti-rabbit secondary antibody. 
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5.2.2.2 Measure of proliferation of Ramos cells in which AID is knocked down, compared to 
control cells, with and without treatment with the chemotherapeutic drug doxorubicin 
One of the features of cancer cells is the ability to proliferate faster than normal cells 
(Hanahan and Weinberg, 2011). In this experiment, cell proliferation was determined by 
measuring cell viability, using WST-1. WST-1 contains tetrazolium salts which are cleaved to 
formazan dye in the presence of cellular enzymes produced by metabolically active cells, thus 
the more cleaved salt, the greater the colour change which indirectly indicates cell viability. 
Cells were plated according to Section 2.12.1, transfected with the respective siRNAs, and 48 
hours post-transfection, the WST-1 reagent was added to the medium. The cell viability was 
measured two hours later using the Glo-Max®-Multi+ multiplate reader (Promega, US). 
Complete remission of adult BL patients is only achieved in 60 to 70 % of adults, with relapse 
resulting in early death, thus this experiment was performed to determine whether sensitivity 
to chemotherapeutic drugs could be achieved with reduced AID expression (Richter-Larrea et 
al., 2010). The chemotherapeutic drug doxorubicin, which is currently part of the regimen 
used for BL patients, was used to treat the cells (Dunleavy et al., 2013). The correct 
concentration of doxorubicin needed to be determined so as to be a high enough 
concentration to induce cell death, but low enough to be able to determine whether a change 
in AID protein expression could alter proliferation. An IC50, which is a process of determining 
how much drug is required to reduce cell viability by half, was performed with a concentration 
gradient of 0.025 to 1 µg/ml and proliferation determined using the WST-1 assay (Figure 5.5). 
This range of concentrations was determined according to the literature published on the 
Ramos cell line (Lee at el., 1999; Nazari et al., 2011). From Figure 5.6 a concentration of 0.5 
µg/ml was selected as the ideal doxorubicin concentration. As shown in Figure 5.5, in the 
untreated cells, there was an approximate 8.6 % decrease in proliferation of the AID-siRNA3 
versus siRNA Neg cells, and an approximate 20.5 % (p < 0.05) decrease in AID-siRNA3 versus 
Ramos control cells. In the presence of doxorubicin, the AID-siRNA3 versus siRNA Neg cells 
had an approximate 27.7 % decrease (p < 0.05) in proliferation and viability, while the AID-
siRNA3 versus Ramos control cells had an approximate 26.5 % decrease (p < 0.05). There was 
an approximate 1.1 % change in proliferation between the siRNA Neg and the Ramos control 
cells in the doxorubicin treated cells. From these results it can clearly be seen that reducing 
AID produces a change in proliferation and viability, which becomes more pronounced when 
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the cells are exposed to doxorubicin thus indicting that cells with decreased AID may be more 
susceptible to chemotherapeutic drugs.  
 
Figure 5.5: Measure of proliferation using the WST-1 assay of normal, AID knock down, and siRNA 
negative control Ramos cells, in the presence or absence of doxorubicin. Proliferation of normal 
Ramos cells and knocked down cells either in the presence of doxorubicin (red) or absence (blue). 
After 48 hours post-knockdown, 4 x 104 cells were placed in 100 µl of medium with 10 µl of WST-1 
reagent and incubated for two hours, after which the absorbance at 450 nm was normalised against 
the control absorbance of 750 nm. Error bars represent the standard deviation. ** represents a p 
value of < 0.01, and * represents a p value of < 0.05 (Prism 6, GraphPad, USA).  
 
 
Figure 5.6: IC50 measure for Ramos cells in the presence of the chemotherapeutic drug, doxorubicin. 
Ramos cells were exposed to a concentration gradient of doxorubicin (0.025 µg/ml to 1 µg/ml) over 
48 hours and the cell viability was determined using the WST-1 assay. Error bars represent the 
standard deviation.  
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5.2.2.3 Measure of proliferation of Ramos cells in which AID is knocked down, compared to 
control cells using BrdU incorporation 
To confirm the WST-1 results above, the BrdU assay was performed. This assay utilises the 
pyrimidine analogue, BrdU, which is added to the medium in which cells are growing. It gets 
incorporated into the replicating DNA of actively dividing cells, replacing the thymidine base 
in nascent DNA. An antibody specific for BrdU, followed by a fluorescently bound secondary 
antibody can then be used to detect the incorporation of these nucleotides. The cells are then 
mounted on slides and visualised under the fluorescent microscope. Figure 5.7 below shows 
that the BrdU nucleotides were incorporated into both the untreated Ramos cells 
(approximately 71 %), as well as the siRNA Neg cells (approximately 85 %) with significantly 





Figure 5.7: BrdU incorporation, as a measure of proliferation in untreated Ramos, siRNA Neg and 
AID-siRNA3 cells. BrdU staining was performed on untreated Ramos cells (A-C), Ramos cells using the 
siRNA Neg (D-F) and Ramos cells where AID was knocked down (G-I). Total cells were counted and 
percent positive cells and the results shown in panel J. BrdU was added to cells 42 hours post-
knockdown, or seeding, and mounted onto glass slides. These cells were stained with mouse anti-BrdU 
(Roche, Germany) followed by the Cy3 donkey anti-mouse secondary antibody (AEC-Amersham, SA). 
Cells were additionally stained with Hoechst stain to visualise the nucleus. Cells were visualised under 
the fluorescent microscope. A, D & G are overlaid fluorescent images, B, E & H are the BrdU fluorescent 
images, and C, F & I are the Hoechst stained images. J is the graph showing the percent positive BrdU 





5.2.2.4 Measure of apoptosis using Annexin V and flow cytometry, with and without 
treatment with the chemotherapeutic drug doxorubicin 
As discussed in Section 4.2.5.3, apoptosis is a process of programmed cell death and cancer 
cells are normally resistant to apoptosis. In this experiment, we wanted to determine whether 
knocking down AID would influence the number of Ramos cells which undergo apoptosis, 
using the Annexin V kit and flow cytometry. Annexin V functions by detecting the 
phospholipid phosphatidylserine (PS) which translocates to the outside of the plasma 
membrane in the early stages of apoptosis. The PS is then accessible to the Annexin V protein 
which has a high affinity for the PS. The Annexin V protein is conjugated to the phycoerythrin 
(PE) fluorochrome and thus detectible using flow cytometry. A second fluorophore called 7-
AAD is used to identify dead/necrotic cells as this protein binds to DNA which is only exposed 
in cells with a compromised plasma membrane. Both Annexin V and 7-AAD are used in 
combination to determine the stage of apoptosis. Ramos cells were additionally exposed to 
the chemotherapeutic drug doxorubicin to determine whether a knockdown in AID 
expression makes the cells more susceptible to apoptosis. As shown in Figure 5.8 below, no 
change in the level of apoptosis was detected between the AID-siRNA3 and the siRNA Neg 
control cells in the untreated cells. In the cells exposed to doxorubicin, there was an increase 
in Annexin V positive cells from 49.75 % in the siRNA Neg cells compared to 56.08 % in the 
AID-siRNA3 cells, thus showing an increase in apoptosis when AID-siRNA3 cells are treated 






Figure 5.8: Flow cytometric analysis of Annexin V and 7-AAD for the siRNA Neg control and AID-
siRNA3 Ramos cells with or without doxorubicin. Panels A-D are the results for the untreated Ramos 
cells, while panels E-H are the Ramos cells exposed to doxorubicin. A is the expression profile of 
Annexin V for the AID-siRNA3 Ramos cells, while B is the 7-AAD expression for the same cell 
population, panel C is the Annexin V profile for the siRNA Neg Ramos cells and panel D is the 7-AAD 
profile for the same cell population. E is the expression profile of Annexin V for the AID-siRNA3 Ramos 
cells with doxorubicin, while F is the 7-AAD expression for the same cell population, panel G is the 
Annexin V profile for the siRNA Neg Ramos cells with doxorubicin and panel H is the 7-AAD profile for 
the same cell population.  
 
5.2.2.5 Measure of migration ability of Ramos cells in which AID has been knocked down, 
compared to control cells, using a Transwell assay 
Cancerous cells have increased motility, as shown during the epithelial-to-mesenchymal 
transition, when epithelial cells move down into the mesenchyme, acquire a mesenchymal 
phenotype, and can progress further by metastasizing to different locations within the body 
(Rokavec et al., 2014). Though B-cells are not of epithelial origin, advanced lymphomas do 
acquire migratory abilities and metastasizes from the lymph nodes to other sites in the body. 
Thus we wanted to determine whether a decrease in AID expression would reduce the 
motility of Ramos cells using a Transwell migration assay as described in Section 2.21. This 
assay functions by plating cells in an upper chamber low in serum conditions (culture medium 
containing 1 % FBS only) separated by a membrane with pores which are small enough to 
prevent the Ramos cells from falling through, but big enough to allow the cells to move 
through the membrane into the lower chamber which contains culture medium with 10 % 
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FBS. The nutrient gradient should induce the cells to move from the upper to the lower 
chamber, where the cells in the lower chamber are stained and quantified based on the 
amount of stain which is incorporated. The Ramos cells with knocked down AID expression 
had an approximate 6 % decrease in migratory ability compared to the siRNA Neg Ramos cells 
(Figure 5.9). Although this result was not significant, the same trend could be observed in all 
three replicate chambers.  
 
Figure 5.9: Migration using the Transwell migration assay of Ramos cells in which AID is knocked 
down, compared to untransfected and siRNA Neg control cells. The migratory ability of the Ramos 
cells were determined by plating the cells in the upper chamber (1 % FBS) of the Transwell plate. The 
number of cells that pass from the upper chamber into the lower chamber (10 % FBS) through the 5 
µm pores were stained with 0.1 % crystal violet. This stain was then solubilised and the intensity, as a 
measure of the number of cells stained, was detected at a wavelength of 600 nm on the GloMax®-
Multi microplate reader (Promega, US). The result was normalised against the total number of cells 
plated, as determined by counting cells in both the upper and lower chambers. The experiment was 
performed in triplicate with the AID knockdown Ramos cells (blue) and siRNA Neg cells (red). Error 
bars represent the standard error of the mean (Prism 6, GraphPad, USA) and no statistical significance 
was detected.    
 
5.2.2.6 Detection of specific CD markers in Ramos cells with knockdown AID expression, 
compared to control cells 
Cluster of differentiation (CD) markers are leukocyte cell surface markers which can be used 
to determine the different stages of cell maturity. Three different CD markers were used in 
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this study, CD19, CD20 and CD10 conjugated to different fluorophores. These three markers 
were selected by comparing the phenotypic profile of the Ramos cells (taken from the DSMZ 
database, Appendix B, Figure B6) to a normal B-cell line to determine which markers may be 
changed with knockdown of AID. The CD19 marker is a highly conserved co-receptor for cell 
growth with high expression which increases throughout B-cell maturation and 
differentiation (Ginaldi et al., 1998), thus CD19 was used as a B-cell selection marker for a 
positive B-cell population. 
 
The CD20 marker is a transmembrane phosphoprotein which has a role is in the calcium 
channel and is important in B-cell activation and differentiation. It also appears later in 
development with mature B-cells having a greater expression compared to precursors. 
(Ginaldi et al., 1998). This marker is expressed on most B-cell non-Hodgkin’s lymphomas but 
is not found on stem cells, pro-B cells, normal plasma cells or normal tissues, and importantly, 
it is the target of the chemotherapeutic agent rituximab which is used to treat B-cell non-
Hodgkin’s lymphomas (Hauptrock and Hess, 2008). 
 
The CD10 marker is also known as enkephalinase which is a human membrane-associated 
neutral endopeptidase (Dogan et al., 2000). CD10 is known to be expressed in activated 
germinal centre B-cells (Alizadeh et al., 2000). It was thought that knocking down AID could 
alter the CD marker expression back to the CD markers expression for a normal lymphoid cell 
line. As shown in Figure 5.10 below, no changes in the cell surface expression of any of the 





Figure 5.10: Flow cytometric analysis of the CD20, CD19 and CD10 cell surface expression in control 
Ramos cells, AID-siRNA3 and siRNA Neg cells. Panel A-D are the expression profiles for the control 
cells, E-H are the AID-siRNA3 cells, and I-L are the siRNA Neg cells. The left panel are the selected cell 
populations, the second panel are the CD20 markers, the third panel are the CD19 markers and the 
final panel are the CD10 markers.  
 
5.2.2.7 Cell cycle profiling of Ramos cells in which AID is knocked down, compared to control 
cells 
Cancer cells often have an altered cell cycle profile (Vermeulen et al., 2003). This is because 
in cancer cells, cell cycle checkpoints are often disrupted. We wanted to determine whether 
knockdown of AID caused alterations in the cell cycle checkpoints with accumulations of cells 
in a specific phase of the cell cycle. This was determined using flow cytometry which detects 
the total amount of DNA content within each cell, and separates the cells according to cell 
cycle phase as described in Section 4.2.5.2. We thus determined the cell cycle profile of 
control Ramos cells and AID knockdown cells using propidium iodide and flow cytometry 
(Section 2.17). Figure 5.11 below shows the results for the control Ramos cells (A-C), Ramos 
cells with reduced AID expression (D-F) and the siRNA Neg control cells (G-I). From these 
results it was shown that the effect of reduced AID expression did not alter the growth phase 




Figure 5.11: Cell cycle profiling of untransfected Ramos cells, cells in which AID is knocked down, 
and siRNA Neg control cells. A is the cell cycle profile of normal untreated Ramos cells, B and C are 
the gated cells. D is the cell cycle profile of Ramos cells with reduced AID expression using AID-siRNA3, 
E and F are the cells that were gated. G is the cell cycle profile of Ramos cells with the control siRNA 
Neg, H and I are the cells that were gated. The sub G1 blue peak represents the apoptotic cells, the 
first red peak are the cells in the G1 phase, the second red peak are the cells in the G2 phase, while 
the shaded black lines represent the S phase cells. 
 
5.3 Discussion and conclusion 
In normal cells, AID is tightly regulated due to its function in incorporating mutations in DNA 
(Zan and Casali, 2013). Overexpression of AID has the potential to have catastrophic 
consequences for the cells and the body. With AID implicated as the cause for the canonical 
c-myc/IgH translocations, which is a hallmark of BL, we wanted to determine what other 
oncogenic functions are associated with this enzyme. Given that an overexpression model of 
AID could not be produced due to the severity of the cellular damage caused by AID (Chapter 
4), a knockdown model was instead generated.  This was successfully achieved using siRNA in 
the BL cell line Ramos. To confirm the results observed and ensure these were not from any 
pleiotropic effects, at least two siRNAs capable of knocking down AID are usually used. AID-
siRNA5 was selected as a second candidate, however, AID knockdown could not be improved 
above the 28 % obtained in Figure 5.2. Being unable to identify a second siRNA from the four 
tested, only AID-siRNA3 was used. A scrambled siRNA was used in conjunction with the AID-
siRNA3 to control for any effects which could be a remnant from the experimental procedure. 
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Once knockdown of AID was reproducibly achieved, specific cellular features were 
investigated. These include, as described in Chapter 1, whether AID induces dsDNA breaks, 
which is linked to the canonical c-myc/IGH translocations observed in BL cells. It was expected 
that a reduction in AID expression would decrease the amount of dsDNA breaks. In the 
presence of dsDNA breaks, the 139th serine residue is phosphorylated on the H2A molecule, 
producing the phosphorylated form of the protein, γ-H2AX (Kuo and Yang, 2008). For every 
dsDNA break, hundreds to thousands of phosphorylated γ-H2AX are recruited which in turn 
causes a DNA damage repair cascade (Kuo and Yang, 2008). As cancer cells have a higher 
phosphorylated γ-H2AX expression, it was of interest to determine whether phosphorylated 
γ-H2AX protein expression was altered with the decrease in AID expression (Kuo and Yang, 
2008). This was shown to be the case with the knockdown of AID in the BL cell line Ramos 
causing a near total reduction in phosphorylated γ-H2AX. The untreated Ramos cells as 
expected produced large quantities of phosphorylated γ-H2AX, while the siRNA Neg had 
reduced, while still high, phosphorylated γ-H2AX expression (Figure 5.4). This difference could 
have been due to loading of the western blot as the Ramos control cells had greater p38 
expression. Thus it can be stated that the abolishment of phosphorylated γ-H2AX protein 
expression is indicative of a decrease in dsDNA breaks. This result highlights that AID is related 
to the induction of dsDNA breaks which adds credence to the implication that AID 
overexpression causes the c-myc/IgH translocations, and is likely responsible for other 
genomic abnormalities in these cells (Ramiro et al., 2006). Love et al. (2012) fully sequenced 
the genome of BL patient and 59 BL tumour exomes and identified 70 genes which were 
regularly mutated in these samples, thus showing that BL cells are subjected to increased 
mutagenesis, as highlighted by the high expression of phosphorylated γ-H2AX protein 
expression.  
 
One of the hallmarks of cancer cells is their ability to proliferate uncontrollably (Hanahan and 
Weinberg, 2011). Thus it was of interest to determine whether the knockdown of AID 
expression caused a decrease in proliferation. The proliferation and viability of the cells was 
determined using the WST-1 assay, and compared to untreated Ramos cells, AID-siRNA3 had 
significantly lower (p < 0.01) proliferation (Figure 5.5). This, approximately 20 % decrease in 
proliferation, highlights a potentially important, though indirect, role for AID in maintaining 
cell viability and proliferation. One of the genes implicated in cellular proliferation is the c-
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Myc proto-oncogene (Neganova and Lako, 2008), which is especially relevant in Ramos as BL 
is classified as having deregulated expression of c-Myc due to the canonical translocation 
between c-Myc and Igh. AID overexpression has been associated with this translocation 
(Duquette et al., 2005) thus a possible mechanism for the reduction in proliferation may be 
due to the reduction of AID, thereby reducing the expression of the c-myc/IgH mutated 
protein. This could also be due to the ability for AID to alter other genes which play a role in 
proliferation. Three such genes were found to be mutated in BL patients, ID3, BRAF and 
CREBBP (Love et al., 2012).  The ID3 gene has been shown to increase cell cycle progression 
and expression of proliferation associated genes (Love et al., 2012), with BRAF having been 
shown to increase cellular growth (Davies et al., 2002) and CREBBP playing a critical role in 
growth control (Huang et al., 2010). It would be of interest to check the c-Myc translocation 
using fluorescent in situ hybridisation (FISH) in the AID knockdown cells as well as to check 
the expression and mutational status of ID3, BRAF and CREBBP.  
 
As previously stated, only 60 – 70 % of adult BL patients achieve complete remission with 
chemotherapeutic treatment (Richter-Larrea et al., 2010) and it has also been shown that BL 
patients respond less effectively to chemotherapeutic drugs (Barta et al., 2015). Even HIV-
positive patients undergoing combined therapy (HAART and chemotherapy) respond poorly 
(Barta et al., 2015). Thus to determine whether knockdown of AID caused the Ramos cells to 
become more sensitive to chemotherapeutic agents, doxorubicin, which is currently part of 
the regimen used to treat BL patients (Dunleavy et al., 2013), was added to the Ramos cells 
and proliferation and viability was determined using the WST-1 assay. Initially an IC50 of 
doxorubicin was determined as no consensus from the literature could be found. An IC50 
looks at how much of a drug is required to reduce the cells by half over a given time point, 
which for this experiment was 48 hours (Figure 5.6). A concentration of 0.5 µg/ml was 
selected as the most effective concentration, as doxorubicin causes cell cycle arrest at G1 and 
G2, thus if the concentration is too low, cells remain in these phases producing cellular 
enzymes detected by WST-1, however, when the concentration increases enough apoptosis 
is induced (Tacar et al., 2013). The results of the WST-1 assay showed a proliferation decrease 
in the untreated cells of 8.6 % and 20.5 % for the AID-siRNA3 cells compared to the siRNA Neg 
and Ramos cells respectively (Figure 5.5). With the doxorubicin treated cells having a 27.7 % 
and 26.5 % decrease in proliferation observed for the AID-siRNA3 knockdown cells compared 
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to the siRNA Neg and Ramos control cells respectively. Thus it can be said that a reduction in 
AID expression does seem to make the Ramos cells more sensitive to the chemotherapeutic 
drug doxorubicin and AID overexpression may confer a greater growth advantage to these 
cancerous cells. Doxorubicin functions by intercalating with DNA, thereby ceasing DNA 
replication, and has been shown to activate the intrinsic apoptotic pathway which indirectly 
permeabilises the mitochondrial membrane by upregulating members of the intrinsic 
apoptotic pathway as described in Chapter 4 (Fulda and Debatin, 2006; Elmore, 2007). This 
cellular sensitivity could be a possible avenue of further research in the development of new 
treatments against cancers, by using AID as a therapeutic target strategy where AID is 
overexpressed, in cancers such as BL. If a treatment involved the addition of an AID repressor 
in conjunction with the chemotherapeutic regime already administered, there could be an 
improvement in the efficacy of treatment, such Wang et al. (2011) showed with the improved 
response of doxorubicin with the addition of ellipticine. Ellipticine is an anti-cancer compound 
that intercalates with DNA, inhibits the topoisomerase II enzyme and has been shown to 
reactivate mutant p53 (Wang et al., 2011; Stiborova et al., 2014).  
 
To confirm the WST-1 assay results, the knocked down Ramos cells were exposed to the 
thymidine analog BrdU, which is incorporated into the DNA of actively dividing cells which can 
then be detected under fluorescence microscopy with the addition of florescent antibodies 
specific to BrdU. The BrdU results correlated with the WST-1 assay results showing that 
knockdown of AID in Ramos cells caused a decrease in proliferation as only 11% of cells were 
positive for BrdU (Figure 5.7). The results of this assay would ideally be repeated with an 
alternative stain as the Hoechst 33342 is quenched by BrdU, however, due to limited reagents 
we were unable to repeat this experiment (Latt, 1977).  
 
Another hallmark of cancer is the cells ability to evade apoptosis (Hanahan and Weinberg, 
2011). To determine whether a reduction in AID protein expression would render these cells 
more susceptible to apoptosis, the Ramos cells were subjected to the Annexin V detection 
assay. No differences were discernible, using the Annexin V assay, between the untreated AID 
knockdown and the control siRNA Ramos cells (Figure 5.8). This result differs from what was 
observed in the flow cytometric analysis which was used to measure the expression of specific 
cell surface markers (Appendix B, Figure B5). In that assay, a significant proportion of 
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apoptotic cells were observed among the AID-siRNA3 cell population, compared to the siRNA 
Neg cells. Compared to the untreated cells, there was approximately an 8 % increase in 
necrotic cells in the doxorubicin treated cells, with less cells in the pre-apoptotic stage of cell 
death (Figure 5.8; A and E). In the cells treated with doxorubicin, there was an increase in 
apoptosis observed in the AID-siRNA3 Annexin V cells compared to the siRNA Neg cells (Figure 
5.8; F and H). This result reflects what was observed in the WST-1 assay earlier where 
proliferation and cell viability decreased in the AID-siRNA3 cells in the presence of doxorubicin 
(Figure 5.5). A possible reason for this could be due to the sensitivity of the Annexin V kit 
which may not pick up these changes due to the assay limitations, such as unbound labelled 
protein adding to the background emissions and false positive results due binding to aldehyde 
adducts (Demchenko, 2013). Future work may look at using the probe F2N12S, which is a 
small fluorescent molecule which is non-fluorescent when unbound and has a high affinity for 
only the outer leaflet of the cell membrane and can be quantified on an absolute scale 
(Demchenko, 2013). 
 
The ability of cells to migrate is yet another key feature of cancer cells, especially in advanced 
stage types of cancers (Hanahan and Weinberg, 2011). The mobility of Ramos cells after AID 
was knocked down was investigated. The results showed that with a reduction in AID, 
migratory ability of these cells was decreased by approximately 6 % with a high level of 
variation (Figure 5.9). This was a very low percent migration which could be due to the fact 
that these are suspension cell lines and the majority of cells used with the Transwell assay 
system are adherent cell lines which do not have the risk of being removed with the washing 
steps. This assay was repeated, however, the knockdown confirmation was not acceptable 
thus these results were not included and due to time limitations it could not be repeated a 
third time. The results indicate that AID may be involved in migration, indirectly, and that 
more replicates will need to be done to validate this result. Love et al. (2012) showed that 
LAMA3, a regulator of cell migration, was mutated in BL patient samples, thus this may be the 
indirect link implicating AID in changes in migratory ability. As previously described in Section 
5.2.2.5, cancerous cells, even of B-cell origin, have increased mobility. It has been shown that 
members of the miRNA-34 family, which inhibit the epithelial-to-mesenchymal transition, are 
induced by p53 (Rokovac et al., 2014). With Ramos cells having a mutated/deficient form of 
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p53 as discussed in Chapter 4, the miRNA-34 family will not be induced, thereby leading to 
increased migration of these cells.      
With the cells seeming to be moving to a more non-cancerous identity, the cells stage of 
differentiation was determined. Three CD markers (CD10, CD19 and CD20) of interest were 
selected, which were all expressed between 98 – 100 % in the untreated Ramos cells 
(Appendix B, Figure B6). During the early development of cells, proliferation is rapid and as 
the cells become more differentiated and mature, proliferation decreases (Cooper, 2000). 
Thus cancerous cells take on a more “immature” cell type with increased proliferation, 
therefore we selected CD10 which is expressed in early immature B-cell development to 
determine whether knockdown of AID would cause the cells to move out of an immature 
cancerous phenotype to a more mature, normal B-cell type (Dogan et al., 2000). The marker 
CD20 was selected as this was the target for rituximab, the first monoclonal antibody 
approved for therapeutic use in cancer patients (Smith et al., 2003). Thus if a reduction in AID 
expression could decrease the CD20 marker expression, this would be indicative of AID 
knockdown as a possible treatment for cancer associated with AID overexpression. The 
marker CD19 is expressed on all B-cells and thus was used as a control B-cell selection (Ginaldi 
et al., 1998).  With the reduction of AID expression, we were unable to detect a change in CD 
marker expression (Figure 5.10). This could be due to the transient nature of the siRNA 
knockdown, we detected after 48 hours and changes in the CD markers may take longer to 
alter to a detectable level by which time the AID knockdown may no longer be in effect or 
alternatively AID may not play a role in the alteration of CD marker expression.   
 
We wanted to determine whether there would be a change in the cell cycle profile of Ramos 
cells with reduced AID expression. Typically cells replicate every 24 hours, however, 
cancerous cells have uncontrolled proliferation and thus are continuously dividing and may 
even have a faster proliferation rate. Cell cycle profiling was assessed to check whether the 
proliferation decrease caused by AID knockdown was due to checkpoints, such as those found 
in G1 and G2, being activated (Lapenna and Giordano, 2009). If these checkpoints were 
activated, cells would have halted or slowed down their proliferation rate. As is shown in 
Figure 5.11, there was no difference between the cell cycle profiles of Ramos cells in which 
AID was knocked down, compared to control cells. As it is known that Ramos is already able 
to bypass these DNA damage checkpoints (Allday et al., 1995), which are compromised in 
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these cells (despite the presence of DNA damage as demonstrated by the expression of 
phosphorylated γ-H2AX). With reduced AID expression, and therefore reduced insult to the 
genome, there was still no difference Future experiments should look at first treating the cells 
with an insult, such as UV light, which would induce further DNA damage and then determine 
the effect on cell cycle profiling. 
 
Thus in this chapter we have shown that reducing AID has an impact on the phenotype of 
these BL cells, thus highlighting the need for cells to regulate its expression and further 
implicating it in cancer development.  
 
Knockdown is a powerful technique which can be used to identify the mechanisms of certain 
genes, however, this technique poses limitations. One of the main limitations is the narrow 
time frame post-knockdown. Tests were performed to determine the optimal time of analysis 
after knockdown which was approximately 48 hours, with certain experiments requiring a 
greater time frame to perform, this reduced the scope of the possible downstream 
experiments. Another consideration is the half-life of AID, which has been shown to be 
approximately 20 hours in the cytoplasm, thus after 48 hours the reduction of AID expression 
may be limited by this high half-life (Aoufouchi et al., 2008). The knockdown experiment was 
optimised, however, due to unknown experimental errors, the knockdown expression was 
not always effective and some experiments required repeating. Due to the high cost of the 
siRNA and that suspension cell lines required over ten times more reagents than adherent 
cells, the cost limited the amount of experiments able to be performed.  
 
This study opens up a wide scope of future work. The knockdown experiments should be 
repeated with a different BL cell line to, firstly, confirm the results, and secondly, to determine 
whether the effect could be altered with a change in p53 classification or EBV expression. 
Alternatively, the siRNA results should be confirmed in Ramos cells using another siRNA, 
possibly from a different company. An alternative to knockdown, which may be more 
effective, would be to use the Crispr-Cas9 system, which uses guide RNAs to disrupt the genes 
of interest (Ran et al., 2013). This is a relatively affordable and highly accurate technique. The 
resulting mutated AID cells would provide a longer time frame in which to perform more 
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experiments such as cell morphology studies, proliferation over a longer period of time, 
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Appendix A: Recipes and reagents 
 
30 % Acryl-bisacrylamide 
 100 ml 
Acrylamide 29 g 
N, N’-methylenebisacrylamide 1 g 
Make up to 100ml with dH2O  
Heat to 37°C to dissolve and filter with a 0.44 µm filter 
 
1 % Agarose gel 
 40 ml 
Agarose 0.4 g 
1X TBE 40 ml 
Pulse heat in a microwave with gentle agitation, before pouring add 2 µl Ethidium Bromide 
(10 mg/ml stock, Sigma- Aldrich)  
 
10 % APS 
 100 µl 
Ammonium Persulfate 100 mg 
dH2O 100 µl 
 
0.1 % crystal violet stain 
 10 ml 
Crystal Violet 100 mg 
2 % Ethanol 100 µl 
 
70 % Ethanol 
 100 ml 
100 % ethanol 70 ml 




0.1 M PIPES 
 20 ml 
PIPES 20 ml 
Milk powder 0.6048 g 
pH to 6.8 
 
1.5 M Tris pH 6.8 
 500 ml 
Tris 60.5 g 
dH2O 300 ml 
pH to 6.8 and adjust volume to 500 ml with dH2O 
 
1.5 M Tris pH 8.8 
 500 ml 
Tris 60.5 g 
dH2O 300 ml 
pH to 8.8 and adjust volume to 500 ml with dH2O 
 
2 N Hydrocholoric acid 
 50 ml 
32 % HCl 19.2 ml 
dH2O 40.4 ml 
 
10X PBS  
 1000 ml 
NaCl 80 g 
KCl 2 g 
Na2HPO4-7H2O 26.8 g 
KH2PO4 2.4 g 




2X RNA loading buffer 
 1000 µl 
Formamide 900 µl 
Sucrose 99 µl 
Bromophenol Blue 0.5 µl 
Xylene Cyanol 0.5 µl 
 
10X Running buffer 
 1000 ml 
SDS 10 g 
Tris 30.3 g 
Glycin 144.1 g 
Make up to 1000 ml with dH2O 
 
1X Running buffer 
 1000 ml 
10X Running Buffer 100 ml 
dH2O 900 ml 
 
10 % SDS 
 100 ml 
SDS 10 g 
dH2O 90 ml 










5X SDS loading dye 
 Volume Final Concentration 
2 M Tris-HCl ph 6.8 12.5 ml 250 mM 
10 % SDS 10 g 10 % 
100 % Glycerol 30 ml 30 % 
β-mercaptoethanol 5 ml 5 % 
0.04 % Bromophenol Blue 52 ml 0.04 % 
 
12% SDS resolving gel 
 Volume 
H2O 3.3 ml 
30 % Acryl-bisacrylamide  4 ml 
1.5 M Tris pH 8.8 2.5 ml 
10 % SDS 100 µl 
10 % APS 100 µl 
TEMED 4 µl 
 
5% SDS stacking gel 
 Volume 
H2O 2.1 ml 
30 % Acryl-bisacrylamide  500 µl 
1.5 M Tris pH 6.8 380 µl 
10 % SDS 30 µl 
10 % APS 30 µl 









10X TBE buffer 
 1000 ml 
Tris 108 g 
Boric Acid 55 g 
dH2O 900 ml 
Add 40 µl 0.5 M Na2EDTA (pH 8.0) and adjust volume to 1000 ml 
 
1X TBE buffer 
 1000 ml 
10X TBE 100 ml 
dH2O 900 ml 
 
1X TBS  
 200 ml 
Tris 1.21 g 
NaCl 1.75 g 
dH2O 200 ml 
 
10X Transfer buffer 
 1000 ml 
Glycine 144 g 
Tris 38 g 
Make up to 1000 ml with dH2O 
 
1X Transfer buffer 
 1000 ml 
10X Transfer Buffer 100 ml 
dH2O 700 ml 
Isopropanol 200 ml 




β-galactosidase fixative (4 % paraformaldehyde) 
 100 ml 
Paraformaldehyde 0.2 g 
1X PBS 5 ml 
Heat to 60 °C to dissolve and store at -20 °C 
 
2X Boiling blue 
 Stock 10 ml 
Tris-HCl pH6.8 1 M 1.25 ml 
SDS 10 % 4 ml 
β-mercaptoethanol  1 ml 
Glycerol  2 ml 
dH2O  1.75 ml 
Bromophenol Blue  Pinch 
Store at -20°C 
 
Borate buffer (0.1 M) 
 100 ml 
Sodium Borate 38.14 g 
dH2O 100 ml 
 
Citric acid buffer 
 Stock 200 ml 
Citric Acid 0.1 M 39.4 ml 
Sodium Phosphate 0.2 M 60.6 ml 
dH2O  100 ml 
 
DEPC-treated H2O 
 100 ml 
DEPC 100 µl 




A ratio of 1:3 Glacial acetic acid:Methanol stored at 4 °C 
 
Mounting fluid 
 Stock 100 ml 
0.1 M Citric Acid 1.05 g/50ml 22.2 ml 
0.2 M Na2HPO4.2H2O 1.41 g/50 ml 27.8 ml 
Glycerol  50 ml 
pH at 5.5 
 
Hoechst 33342 stain (#H1399, Invitrogen, USA) 
A stock of 10 mg/ml was diluted in dH2O in a 1:15000 ratio 
 
5 M NaCl 
 20 ml 
NaCl 5.84 g 




1X PBS 100 ml 
Tween 1 ml 
Make up to 1000ml with dH2O 
 
PBS/Tween + 5 % milk powder 
 100 ml 
PBS/Tween 100 ml 






Propidium iodide stain 
 Stock 8 ml 
Triton X-100 100 % 8 µl 
MgCl2 1 M 16 µl 
NaCl 5 M 160 µl 
PIPES 0.1 M 800 µl 
Propidium Iodide 1 mg/ml 80 µl 
dH2O  6.936 ml 
 
RIPA buffer 
 Stock 50 ml 
150 nM NaCl 5 M 1.5 ml 
1% Triton X-100 100 % 500 µl 
0.1% SDS 10 % 500 µl 
10 mM Tris pH 7.5 1 M 500 µl 
1% Deoxycholate powder  0.5 g 
Make up to 50 ml with dH2O 
 
RIPA solution 
 1 ml 
RIPA Buffer 858 µl 
7X Protease Inhibitor 142 µl 
 
Striping buffer 
 Stock Final Concentration 100 ml 
β-mercaptoethanol 14.3 M 100 mM 0.69 ml 
SDS 20 % 2 % 10 ml 
Tris-HCl (pH 6.7) 1 M 62.5 mM 6.25 ml 







1X TBS 100 ml 
Tween 1 ml 
 
TBS/Tween + 5 % BSA 
 5 ml 
TBS/Tween 5 ml 
BSA 0.25 g 
 
Trypsin-EDTA 
 1000 ml 
NaCl 8 g 
Na2HPO4 1.26 g 
KCl 0.2 g 
KH2PO4 0.2 g 
Trypsin 0.5 g 
EDTA 0.2 g 
Make up to 1000 ml with dH2O at pH 7.4 and filter sterilise (0.2 µm) 
 
X-gal staining solution 
 Stock 1155 µl 
Citric Acid/Sodium Phosphate Buffer 40 mM 1000 µl 
Potassium Ferricyanide 100 mM 50 µl 
Potassium Ferrocyanide 100 mM 50 µl 
MgCl2 200 mM 10 µl 
NaCl 6M 25 µl 
X-gal 50 mg/ml 20 µl 




Appendix B: Additional figures 
 
Figure B1: Gel electrophoresis of total RNA extracted from the prostate cell lines. The two sharp 
bands representing the 28S and 18S ribosomal subunits were observed in a 1 % agarose gel. (Lanes 1 
– 5; Du145, LnCaP, PC-3, PNT1A and PNT2). 
 
 
Figure B2: Gel electrophoresis of total RNA extracted from the oesophageal and head and neck 
cancer cell lines. The two sharp bands representing the 28S and 18S ribosomal subunits were 
observed in a 1 % agarose gel. (Lanes 1 – 5; KYSE-30, KYSE-520, OE19, OE33 and UMSCC22b). 
 
 
Figure B3: Gel electrophoresis of total RNA extracted from L1439A and the Burkitt’s lymphoma cell 
lines. The two sharp bands representing the 28S and 18S ribosomal subunits were observed in a 1 % 






Figure B4: Representative knockdown confirmation of AID reduction in the selected downstream 
experiments. Western blot analysis displaying the protein expression levels of AID after these cells 
had been knocked down for the cell cycle profiling, WST-1, γ-H2AX and BrdU experiments using 1000 
ng of each siRNA. 12 µl of protein in 2X boiling blue buffer was boiled at 95 °C for 10 minutes before 
being loaded and separated on a 12 % SDS-PAGE gel at 100 V for 200 minutes in 1X running buffer. 
The protein was then transferred onto a nitrocellulose membrane (Bio-Rad) for 75 minutes at 100 V 
in 1X transfer buffer. This was then detected using the Clarity™ Western ECL Substrate (Bio-Rad). To 
detect AID, mouse anti-AID (Invitrogen) was used, with a HRP bound goat anti-mouse secondary 
antibody (Bio-Rad). The p38 protein was detected using the rabbit anti-p38 antibody (Sigma-Aldrich) 
and the HRP bound goat anti-rabbit secondary antibody. 
 
 
Figure B5: Expression profiles in control Ramos cells, AID-siRNA3 and siRNA Neg cells. Panel A is the 
expression profiles for the control cells, panel B is the AID-siRNA3 cells and panel C is the siRNA Neg 





Figure B6: Flow cytometric analysis of the CD19, CD10 and CD20 cell surface expression in Ramos 
cells from the DSMZ database. Panel A is the expression profiles for the Ramos cells, B is expression 
profile for CD10, C is the expression profile for CD19 and D is the expression profile for CD20.  Images 




Figure B7: qPCR melting profile of AID. Melting profile of AID utilising a 1:10 serial dilution from 1 x 








Figure B8: Expression profiles in Ramos cells nucleofected with pEGFP-N3-Empty and pEGFP-N3-AID. 




Appendix C: Additional images 
 
Figure C1: Diagram of the pEGFP-N3 vector. AID was cloned into the BamHI and EcoRI site.  
 
 




Figure C3: Diagram of the pCMV-β-Gal vector.   
 
 





Figure C5: GeneRuler™ 1 kb DNA Ladder (Thermo Scientific™, USA). 
